Cigna (CI) 10-Q 4 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38769
Entity Registrant Name	Cigna Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4991898
Entity Address, Address Line One	900 Cottage Grove Road
Entity Address, City or Town	Bloomfield
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06002
City Area Code	860
Local Phone Number	226-6000
Title of 12(b) Security	Common Stock, Par Value $0.01
Trading Symbol	CI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		305,116,202
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001739940

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues
Premiums	$ 10,426	$ 10,323	$ 20,782	$ 20,537
Net investment income	325	310	739	701
TOTAL REVENUES	45,480	43,131	89,485	84,102
Benefits and expenses
Pharmacy and other service costs	31,150	29,001	60,963	56,236
Medical costs and other benefit expenses	8,192	8,484	16,460	16,489
Selling, general and administrative expenses	3,256	2,996	6,555	6,275
Amortization of acquired intangible assets	501	503	959	998
TOTAL BENEFITS AND EXPENSES	43,099	40,984	84,937	79,998
Income from operations	2,381	2,147	4,548	4,104
Interest expense and other	(301)	(298)	(600)	(612)
Debt extinguishment costs	0	(10)	0	(141)
Net realized investment gains (losses)	(95)	59	(414)	60
Income before income taxes	1,985	1,898	3,534	3,411
TOTAL INCOME TAXES	413	422	764	764
Net income	1,572	1,476	2,770	2,647
Less: Net income attributable to noncontrolling interests	13	9	28	19
SHAREHOLDERS' NET INCOME	$ 1,559	$ 1,467	$ 2,742	$ 2,628
Shareholders' net income per share
Basic (in dollars per share)	$ 4.95	$ 4.30	$ 8.66	$ 7.62
Diluted (in dollars per share)	$ 4.90	$ 4.25	$ 8.57	$ 7.54
Pharmacy revenues
Revenues
Revenues	$ 31,972	$ 30,047	$ 62,669	$ 58,072
Fees and other revenues
Revenues
Revenues	$ 2,757	$ 2,451	$ 5,295	$ 4,792

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 1,572	$ 1,476	$ 2,770	$ 2,647
Other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives	(410)	122	(970)	(151)
Net translation gains (losses) on foreign currencies	(206)	16	(269)	(103)
Postretirement benefits liability adjustment	27	15	40	33
Other comprehensive income (loss), net of tax	(589)	153	(1,199)	(221)
Total comprehensive income	983	1,629	1,571	2,426
Comprehensive income (loss) attributable to noncontrolling interests
Net income attributable to redeemable noncontrolling interests	2	3	5	8
Net income attributable to other noncontrolling interests	11	6	23	11
Other comprehensive loss attributable to redeemable noncontrolling interests	(1)	(1)	(3)	(5)
Total comprehensive income attributable to noncontrolling interests	12	8	25	14
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 971	$ 1,621	$ 1,546	$ 2,412

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Jun. 30, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 4,421	$ 5,081
Investments		754	920
Accounts receivable, net		18,290	15,071
Inventories		3,781	3,722
Other current assets		1,124	1,283
Assets of businesses held for sale		9,052	10,057
Total current assets		37,422	36,134
Long-term investments		16,724	18,438
Reinsurance recoverables		4,874	4,970
Deferred policy acquisition costs		742	677
Property and equipment		3,659	3,692
Goodwill		45,810	45,811
Other intangible assets		33,276	34,102
Other assets		2,628	2,728
Separate account assets		7,495	8,337
TOTAL ASSETS		152,630	154,889
Liabilities
Current insurance and contractholder liabilities		5,654	5,318
Pharmacy and other service costs payable		16,432	15,309
Accounts payable		7,142	6,655
Accrued expenses and other liabilities		7,742	7,322
Short-term debt		2,397	2,545
Liabilities of businesses held for sale		5,851	6,423
Total current liabilities		45,218	43,572
Non-current insurance and contractholder liabilities		11,777	12,563
Deferred tax liabilities, net		8,014	8,346
Other non-current liabilities		3,175	3,762
Long-term debt		30,984	31,125
Separate account liabilities		7,495	8,337
TOTAL LIABILITIES		106,663	107,705
Contingencies — Note 18
Redeemable noncontrolling interests		45	54
Shareholders' equity
Common stock	[1]	4	4
Additional paid-in capital		29,930	29,574
Accumulated other comprehensive loss		(2,080)	(884)
Retained earnings		34,626	32,593
Less: Treasury stock, at cost		(16,588)	(14,175)
TOTAL SHAREHOLDERS' EQUITY		45,892	47,112
Other noncontrolling interests		30	18
Total equity		45,922	47,130
Total liabilities and equity		$ 152,630	$ 154,889
[1]Par value per share, $0.01; shares issued, 397 million as of June 30, 2022 and 394 million as of December 31, 2021; authorized shares, 600 million.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	397,000,000	394,000,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Shareholders’ Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2020	$ 50,328	$ 50,321	$ 4	$ 28,975	$ (861)	$ 28,575	$ (6,372)	$ 7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	342	342		431			(89)
Other comprehensive income (loss)	(216)	(216)			(216)
Net income	2,639	2,628				2,628		11
Common dividends declared	(690)	(690)				(690)
Repurchase of common stock	(3,673)	(3,673)		0			(3,673)
Other transactions impacting noncontrolling interests	(14)	(3)		(3)				(11)
Balance at Jun. 30, 2021	48,716	48,709	4	29,403	(1,077)	30,513	(10,134)	7
Balance at Dec. 31, 2020	58
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(5)
Net income	8
Other transactions impacting noncontrolling interests	(10)
Balance at Jun. 30, 2021	51
Balance at Mar. 31, 2021	48,155	48,149	4	29,254	(1,231)	29,389	(9,267)	6
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	150	150		152			(2)
Other comprehensive income (loss)	154	154			154
Net income	1,473	1,467				1,467		6
Common dividends declared	(343)	(343)				(343)
Repurchase of common stock	(865)	(865)		0			(865)
Other transactions impacting noncontrolling interests	(8)	(3)		(3)				(5)
Balance at Jun. 30, 2021	48,716	48,709	4	29,403	(1,077)	30,513	(10,134)	7
Balance at Mar. 31, 2021	59
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(1)
Net income	3
Other transactions impacting noncontrolling interests	(10)
Balance at Jun. 30, 2021	51
Balance at Dec. 31, 2021	47,130	47,112	4	29,574	(884)	32,593	(14,175)	18
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	283	283		356			(73)
Other comprehensive income (loss)	(1,196)	(1,196)			(1,196)
Net income	2,765	2,742				2,742		23
Common dividends declared	(709)	(709)				(709)
Repurchase of common stock	(2,340)	(2,340)		0			(2,340)
Other transactions impacting noncontrolling interests	(11)	0		0				(11)
Balance at Jun. 30, 2022	45,922	45,892	4	29,930	(2,080)	34,626	(16,588)	30
Balance at Dec. 31, 2021	54
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(3)
Net income	5
Other transactions impacting noncontrolling interests	(11)
Balance at Jun. 30, 2022	45
Balance at Mar. 31, 2022	46,109	46,087	4	29,736	(1,492)	33,420	(15,581)	22
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	193	193		194			(1)
Other comprehensive income (loss)	(588)	(588)			(588)
Net income	1,570	1,559				1,559		11
Common dividends declared	(353)	(353)				(353)
Repurchase of common stock	(1,006)	(1,006)		0			(1,006)
Other transactions impacting noncontrolling interests	(3)	0		0				(3)
Balance at Jun. 30, 2022	45,922	$ 45,892	$ 4	$ 29,930	$ (2,080)	$ 34,626	$ (16,588)	$ 30
Balance at Mar. 31, 2022	55
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(1)
Net income	2
Other transactions impacting noncontrolling interests	(11)
Balance at Jun. 30, 2022	$ 45

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	3 Months Ended						6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 1.12	$ 1.12	$ 1	$ 1	$ 1	$ 1	$ 2.24	$ 2

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities
Net income		$ 2,770	$ 2,647
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,476	1,446
Realized investment (gains) losses, net		414	(60)
Deferred income tax (benefit)		(167)	(80)
Debt extinguishment costs		0	141
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable		(2,769)	(3,233)
Inventories		(59)	124
Deferred policy acquisition costs		(105)	(117)
Reinsurance recoverable and Other assets		265	(416)
Insurance liabilities		474	677
Pharmacy and other service costs payable		1,124	1,123
Accounts payable and Accrued expenses and other liabilities		(134)	(1,643)
Other, net		(15)	188
NET CASH PROVIDED BY OPERATING ACTIVITIES		3,274	797
Proceeds from investments sold:
Debt securities and equity securities		1,239	852
Investment maturities and repayments:
Debt securities and equity securities		863	672
Commercial mortgage loans		69	96
Other sales, maturities and repayments (primarily short-term and other long-term investments)		745	897
Investments purchased or originated:
Debt securities and equity securities		(2,024)	(1,999)
Commercial mortgage loans		(84)	(129)
Other (primarily short-term and other long-term investments)		(849)	(1,136)
Property and equipment purchases, net		(612)	(500)
Acquisitions, net of cash acquired		0	(1,836)
Divestiture, net of cash sold		(57)	0
Other, net		(22)	59
NET CASH (USED IN) INVESTING ACTIVITIES		(732)	(3,024)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds		84	96
Withdrawals and benefit payments from contractholder deposit funds		(94)	(96)
Net change in short-term debt		(244)	472
Payments for debt extinguishment		0	(136)
Repayment of long-term debt		0	(4,578)
Net proceeds on issuance of long-term debt		0	4,260
Repurchase of common stock		(2,374)	(3,710)
Issuance of common stock		217	290
Common stock dividend paid		(709)	(687)
Other, net		33	(24)
NET CASH (USED IN) FINANCING ACTIVITIES		(3,087)	(4,113)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash		(80)	(27)
Net (decrease) in cash, cash equivalents and restricted cash		(625)	(6,367)
Cash, cash equivalents and restricted cash January 1,	[1]	5,548	10,245
Cash, cash equivalents and restricted cash, June 30,		4,923	3,878
Cash and cash equivalents reclassified to Assets of businesses held for sale		(455)	0
Total cash, cash equivalents and restricted cash and cash equivalents	[2]	4,468	3,878
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds		911	1,473
Interest paid		$ 615	$ 639
[1]Includes $425 million reported in Assets of businesses held for sale as of January 1, 2022.[2]Restricted cash and cash equivalents were reported in Other long-term investments as of June 30, 2022 and June 30, 2021.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Statement of Cash Flows [Abstract]
Cash and cash equivalents reclassified to Assets of businesses held for sale	$ 455	$ 425	$ 0

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as "Cigna," the "Company," "we," "our" or "us") is a global health services organization with a mission of helping those we serve improve their health, well-being and peace of mind by making health care affordable, predictable and simple. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and supplemental products and services. The majority of these products are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these ongoing operations, Cigna also has certain run-off operations. Details of the Company's reporting segments and recent changes are provided below: On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb INA Holdings, Inc. ("Chubb") for approximately $5.4 billion in cash (the "Chubb Transaction"); as previously agreed, we excluded our interest in a joint venture in Türkiye from the Chubb Transaction. The Company aggregated and classified the assets and liabilities of these businesses as held for sale in our Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (see Note 5). During the fourth quarter of 2021, in connection with the Chubb Transaction, we revised our business reporting structure and adjusted our segment reporting accordingly. Segment results for the three and six months ended June 30, 2021 have been restated to conform to the new segment presentation (see Note 19). A full description of our segments follows: Evernorth includes a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits services, specialty pharmacy and care services, which are provided to health plans, employers, government organizations, and health care providers. Cigna Healthcare includes U.S. Commercial, U.S. Government and International Health operating segments that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans both on and off the public exchanges. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Other Operations contains the remainder of our business operations, consisting of the following: • Ongoing business: • Corporate-Owned Life Insurance ("COLI") offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. • Our interest in a joint venture in Türkiye. • Exiting businesses: • International Life, Accident and Supplemental Benefits Businesses in six countries sold on July 1, 2022 pursuant to the Chubb Transaction. • Run-off businesses: • Reinsurance: predominantly comprised of guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013. • Settlement Annuity and other businesses in run-off. • Individual Life Insurance and Annuity and Retirement Benefits businesses: deferred gains from the sales of these businesses. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and enterprise-wide project costs and intersegment eliminations for products and services sold between segments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. Recent Accounting Pronouncements There were no new accounting standards adopted as of June 30, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Insurance Contracts ("LDTI") that are expected to impact Cigna's operations or our financial statements. Refer to the Company's 2021 Form 10-K for discussion of the LDTI standard and related expected effects to Cigna. We continue to make progress on our LDTI implementation plan and are on track for the January 1, 2023 adoption date. In July 2022, the Financial Accounting Standards Board ("FASB") issued a proposed standard for comment that would simplify the retrospective adoption of LDTI. The proposal would permit companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. If the FASB approves the proposed standard, Cigna expects to make this policy election for the contracts sold in the Chubb Transaction.

Accounts Receivable, Net

Accounts Receivable, Net	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Accounts Receivable, Net	Note 3 – Accounts Receivable, Net The following amounts were included within Accounts receivable, net: (In millions) June 30, 2022 December 31, 2021 Noninsurance customer receivables $ 7,578 $ 6,274 Pharmaceutical manufacturers receivables 7,006 5,463 Insurance customer receivables 2,790 2,932 Other receivables 952 456 Total 18,326 15,125 Accounts receivable, net classified as Assets of businesses held for sale (36) (54) Accounts receivable, net per Consolidated Balance Sheets $ 18,290 $ 15,071

Mergers, Acquisitions and Dives

Mergers, Acquisitions and Divestitures	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Divestitures	Note 4 – Mergers, Acquisitions and Divestitures Acquisition of MDLIVEOn April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. ("MDLIVE"), a 24/7 virtual care platform. Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE. The Company's 2021 Form 10-K includes detailed disclosures of merger consideration, purchase price allocation and intangible assets identified in this transaction. In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's estimates of their fair values and was finalized as of March 31, 2022 with immaterial changes to the purchase price allocation.The results of MDLIVE have been included in the Company's Consolidated Financial Statements from the date of the acquisition. Revenues from MDLIVE and their results of operations were not material to Cigna's consolidated results of operations for the three and six months ended June 30, 2021. The pro forma effects of this acquisition for prior periods were not material to our consolidated results of operations.Integration and Transaction-related CostsIn the first six months of 2022 and 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business and the terminated merger with Elevance Health, Inc. ("Elevance"), formerly known as Anthem, Inc. In the first six months of 2022, the Company also incurred costs related to the Chubb Transaction (see Note 5 for further information). These costs were $36 million pre-tax ($26 million after-tax) for the three months ended and $88 million pre-tax ($63 million after-tax) for the six months ended June 30, 2022, compared with $16 million pre-tax ($14 million after-tax) for the three months ended and $45 million pre-tax ($36 million after-tax) for the six months ended June 30, 2021. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs.

Assets and Liabilities of Busin

Assets and Liabilities of Businesses Held for Sale	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	Note 5 – Assets and Liabilities of Businesses Held for Sale On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for approximately $5.4 billion in cash. The Company aggregated and classified the assets and liabilities of these businesses as held for sale in our Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021. The assets and liabilities of our interest in a joint venture in Türkiye were classified as held for sale in our Consolidated Balance Sheet as of December 31, 2021; however, we subsequently agreed to exclude this business from the Chubb Transaction and the assets and liabilities are no longer classified as held for sale. The assets and liabilities of businesses held for sale were as follows: (In millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 455 $ 406 Investments 4,518 5,109 Deferred policy acquisition costs 2,598 2,755 Separate account assets 648 878 Goodwill, other intangible assets and all other assets 833 909 Total assets of businesses held for sale 9,052 10,057 Insurance and contractholder liabilities 4,427 4,644 Accounts payable, accrued expenses and other liabilities 420 452 Deferred tax liabilities, net 356 449 Separate account liabilities 648 878 Total liabilities of businesses held for sale $ 5,851 $ 6,423

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 6 – Earnings Per Share ("EPS")Basic and diluted earnings per share were computed as follows: Three Months Ended June 30, 2022 June 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,559 $ 1,559 $ 1,467 $ 1,467 Shares: Weighted average 315,122 315,122 341,479 341,479 Common stock equivalents 3,182 3,182 3,450 3,450 Total shares 315,122 3,182 318,304 341,479 3,450 344,929 EPS $ 4.95 $ (0.05) $ 4.90 $ 4.30 $ (0.05) $ 4.25 Six Months Ended June 30, 2022 June 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 2,742 $ 2,742 $ 2,628 $ 2,628 Shares: Weighted average 316,795 316,795 344,845 344,845 Common stock equivalents 2,989 2,989 3,589 3,589 Total shares 316,795 2,989 319,784 344,845 3,589 348,434 EPS $ 8.66 $ (0.09) $ 8.57 $ 7.62 $ (0.08) $ 7.54 The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Anti-dilutive options 1.3 1.5 2.0 1.5

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 7 – Debt The outstanding amounts of debt and finance leases were as follows: (In millions) June 30, 2022 December 31, 2021 Short-term debt Commercial paper $ 1,797 $ 2,027 $500 million, 3.05% Notes due 11/2022 497 495 $17 million, 8.3% Notes due 1/2023 17 — $63 million, 7.65% Notes due 3/2023 63 — Other, including finance leases 23 23 Total short-term debt $ 2,397 $ 2,545 Long-term debt $17 million, 8.3% Notes due 2023 $ — $ 17 $63 million, 7.65% Notes due 2023 — 63 $700 million, Floating Rate Notes due 2023 699 699 $1,000 million, 3% Notes due 2023 989 985 $1,187 million, 3.75% Notes due 2023 1,186 1,185 $500 million, 0.613% Notes due 2024 499 498 $1,000 million, 3.5% Notes due 2024 987 983 $900 million, 3.25% Notes due 2025 (1) 895 897 $2,200 million, 4.125% Notes due 2025 2,194 2,193 $1,500 million, 4.5% Notes due 2026 1,503 1,504 $800 million, 1.25% Notes due 2026 797 796 $1,500 million, 3.4% Notes due 2027 1,429 1,423 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 596 $3,800 million, 4.375% Notes due 2028 3,783 3,782 $1,500 million, 2.4% Notes due 2030 1,491 1,490 $1,500 million, 2.375% Notes due 2031 (1) 1,414 1,500 $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 2,192 2,192 $750 million, 3.2% Notes due 2040 743 743 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 489 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,466 1,465 $1,000 million, 3.875% Notes due 2047 989 988 $3,000 million, 4.9% Notes due 2048 2,968 2,967 $1,250 million, 3.4% Notes due 2050 1,236 1,236 $1,500 million, 3.4% Notes due 2051 1,476 1,477 Other, including finance leases 35 28 Total long-term debt $ 30,984 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments. Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of June 30, 2022, there were no outstanding balances under these revolving credit agreements. In April 2022, Cigna entered into the following revolving credit agreements (the "Credit Agreements"): • a $3.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2027 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $3.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. • a $1.0 billion three-year revolving credit agreement that will mature in April 2025 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. • a $1.0 billion 364-day revolving credit agreement that will mature in April 2023. Cigna can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion. Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across all three facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on Cigna's senior unsecured credit ratings. Each of the three facilities is diversified among 22 banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing on April 2026; a $1.0 billion three-year revolving credit agreement maturing on April 2024; and a $1.0 billion 364-day revolving credit agreement maturing in April 2022. Commercial Paper. Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper average interest rate was 1.60% at June 30, 2022. The Company was in compliance with its debt covenants as of June 30, 2022.

Common and Preferred Stock

Common and Preferred Stock	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Common and Preferred Stock	Note 8 – Common and Preferred Stock Dividends In the first and second quarters of 2022, Cigna declared quarterly cash dividends of $1.12 per share of Cigna common stock. In 2021, Cigna initiated and declared quarterly cash dividends of $1.00 per share of Cigna common stock. The following table provides details of Cigna's dividend payments for the six months ended June 30: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 June 8, 2022 June 23, 2022 $1.12 $352 2021 March 10, 2021 March 25, 2021 $1.00 $345 June 8, 2021 June 23, 2021 $1.00 $342 On July 27, 2022, the Board of Directors declared the third quarter cash dividend of $1.12 per share of Cigna common stock to be paid on September 22, 2022 to shareholders of record on September 7, 2022. Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant. Accelerated Share Repurchase Agreements On June 15, 2022, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("ASR agreements") with Mizuho Markets Americas LLC and Morgan Stanley & Co. LLC (collectively, the "Counterparties") to repurchase $3.5 billion of common stock in aggregate. The ASR agreements provided that if the public announcement of the first closing of the Chubb Transaction did not occur on or before July 1, 2022, the ASR Agreements would be cancelled in whole.

Insurance and Contractholder Li

Insurance and Contractholder Liabilities	6 Months Ended
	Jun. 30, 2022
Insurance Loss Reserves [Abstract]
Insurance and Contractholder Liabilities	Note 9 – Insurance and Contractholder Liabilities A. Account Balances – Insurance and Contractholder Liabilities The Company's insurance and contractholder liabilities were comprised of the following: June 30, 2022 December 31, 2021 June 30, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 371 $ 6,606 $ 6,977 $ 352 $ 6,702 $ 7,054 $ 7,122 Future policy benefits 246 8,454 8,700 312 9,194 9,506 9,531 Unearned premiums 575 415 990 558 418 976 912 Unpaid claims and claim expenses Cigna Healthcare 4,432 58 4,490 4,159 102 4,261 4,228 Other Operations 506 195 701 548 180 728 722 Total 6,130 15,728 21,858 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (476) (3,951) (4,427) (611) (4,033) (4,644) Total insurance and contractholder liabilities $ 5,654 $ 11,777 $ 17,431 $ 5,318 $ 12,563 $ 17,881 $ 22,515 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.6 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of June 30, 2022 and $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Insurance and contractholder liabilities expected to be paid within one year are classified as current. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the six months ended June 30 was as follows: Six Months Ended (In millions) June 30, 2022 June 30, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 15,751 15,716 Prior years (268) (228) Total incurred 15,483 15,488 Paid costs related to: Current year 11,900 12,065 Prior years 3,290 2,858 Total paid 15,190 14,923 Ending balance, net 4,293 4,023 Add: Reinsurance and other amounts recoverable 197 205 Ending balance $ 4,490 $ 4,228 Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsurance. Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the six months ended June 30 were as follows: Six Months Ended (Dollars in millions) June 30, 2022 June 30, 2021 $ % (1) $ % (2) Actual completion factors $ 84 0.2 % $ 92 0.3 % Medical cost trend 184 0.6 136 0.5 Total favorable variance $ 268 0.8 % $ 228 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020. Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions. Liability balance details. The liability details for unpaid claims and claim expenses are as follows. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) June 30, 2022 June 30, 2021 Other Operations International businesses held for sale and our interest in a joint venture in Türkiye $ 412 $ 438 Other Operations 289 284 Unpaid claims and claim expenses - Other Operations $ 701 $ 722 Activity in the unpaid claims and claim expenses for international businesses held for sale and our interest in a joint venture in Türkiye is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Six Months Ended (In millions) June 30, 2022 (1) June 30, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 490 501 Prior years 4 (4) Total incurred 494 497 Paid claims related to: Current year 306 314 Prior years 187 181 Total paid 493 495 Foreign currency (28) (16) Ending balance, net 374 393 Add: Reinsurance 38 45 Ending balance $ 412 $ 438 (1) Includes unpaid claims amounts classified as Liabilities of businesses held for sale. Reinsurance in the table above reflects amounts due from reinsurers related to unpaid claims liabilities. See Note 10 for additional information on reinsurance.

Reinsurance

Reinsurance	6 Months Ended
	Jun. 30, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	Note 10 – Reinsurance The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables. The Company's reinsurance recoverables as of June 30, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 173 $ 173 BBB- to BBB+ equivalent current credit ratings (1) — — 61 61 Not rated 125 4 43 172 Total recoverables related to ongoing operations (2) 125 4 277 406 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,870 — 2,870 Berkshire Hathaway Life Insurance Company of Nebraska 260 428 — 688 Prudential Retirement Insurance and Annuity (marketed under Empower brand) 140 — — 140 Prudential Insurance Company of America 394 — — 394 Life Insurance Company of North America — 401 — 401 Other 208 19 16 243 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or run-off activities 1,002 3,731 19 4,752 Total $ 1,127 $ 3,735 $ 296 $ 5,158 Allowance for uncollectible reinsurance (30) Total reinsurance recoverables (2) $ 5,128 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $164 million of current reinsurance recoverables that are reported in Other current assets and $90 million of recoverables classified as Assets of businesses held for sale as of June 30, 2022. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. The Company entered into an agreement with Berkshire to effectively exit the GMDB and GMIB business via a reinsurance transaction in 2013. Berkshire reinsured 100% of the Company's future claim payments in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.1 billion remaining at June 30, 2022. GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K. GMDB The GMDB exposure arises under annuities written by ceding companies that guarantee the benefit received at death. The Company's exposure arises when the guaranteed minimum death benefit exceeds the fair value of the related mutual fund investments at the time of a contractholder's death. The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) June 30, 2022 December 31, 2021 Account value $ 7,626 $ 9,795 Net amount at risk $ 2,264 $ 1,392 Number of contractholders (estimated) 160,000 170,000 GMIB The Company reinsured contracts with issuers of GMIB products. The Company's exposure represents the excess of a contractually guaranteed amount over the level of variable annuity account values. Payment by the Company depends on the actual account value in the related underlying mutual funds and the level of interest rates when the contractholders elect to receive minimum income payments that can only occur within 30 days of a policy anniversary after the appropriate waiting period. The Company has purchased retrocessional coverage ("GMIB assets") for these contracts including retrocessional coverage from Berkshire. GMIB liabilities totaling $463 million as of June 30, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of June 30, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer June 30, 2022 December 31, 2021 Collateral and Other Terms at June 30, 2022 GMIB Berkshire $ 230 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 136 167 Liberty Re (Bermuda) Ltd. 123 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 489 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Investments [Abstract]
Investments	Note 11 – Investments Cigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 12 for information about the valuation of the Company's investment portfolio. Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. The following table summarizes the Company's investments by category and current or long-term classification: June 30, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 784 $ 13,166 $ 13,950 $ 796 $ 16,162 $ 16,958 Equity securities 69 767 836 — 603 603 Commercial mortgage loans 13 1,566 1,579 40 1,526 1,566 Policy loans — 1,325 1,325 — 1,338 1,338 Other long-term investments — 4,107 4,107 — 3,574 3,574 Short-term investments 199 — 199 428 — 428 Total 1,065 20,931 21,996 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (311) (4,207) (4,518) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 754 $ 16,724 $ 17,478 $ 920 $ 18,438 $ 19,358 (1) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. These investments are primarily comprised of debt securities and other long-term investments, and to a lesser extent, equity securities and short-term investments. See Note 5 to the Consolidated Financial Statements for additional information. The amortized cost and fair value by contractual maturity periods for debt securities were as follows at June 30, 2022: (In millions) Amortized Fair Due in one year or less $ 820 $ 813 Due after one year through five years 4,655 4,454 Due after five years through ten years 4,844 4,407 Due after ten years 4,206 3,909 Mortgage and other asset-backed securities 399 367 Total $ 14,924 $ 13,950 Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties. Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair June 30, 2022 Federal government and agency $ 303 $ — $ 56 $ (6) $ 353 State and local government 157 — — (12) 145 Foreign government 2,471 — 63 (203) 2,331 Corporate 11,594 (45) 151 (946) 10,754 Mortgage and other asset-backed 399 — 2 (34) 367 Total $ 14,924 $ (45) $ 272 $ (1,201) $ 13,950 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,266 $ (5) $ 220 $ (185) $ 2,296 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of June 30, 2022 and December 31, 2021. June 30, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 8,378 $ 9,258 $ (880) 2,695 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 1,124 1,252 (128) 1,405 561 578 (17) 781 More than one year Investment grade 750 916 (166) 355 382 412 (30) 143 Below investment grade 191 218 (27) 134 162 170 (8) 53 Total $ 10,443 $ 11,644 $ (1,201) 4,589 $ 3,890 $ 4,021 $ (131) 1,886 Equity Securities The following table provides the values of the Company's equity security investments as of June 30, 2022 and December 31, 2021: June 30, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 831 $ 426 $ 257 $ 207 Equity securities with no readily determinable fair value 283 410 270 396 Total $ 1,114 $ 836 $ 527 $ 603 Approximately 65% of our investments in equity securities are in the health care sector, consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry. The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of June 30, 2022 and December 31, 2021: (Dollars in millions) June 30, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 850 2.21 $ 560 2.18 60% to 79% 567 1.49 883 1.89 80% to 100% 108 1.21 129 1.47 Greater than 100% 63 1.04 — — Allowance for credit losses (9) (6) Total $ 1,579 1.84 59 % $ 1,566 1.96 61 % Other Long-Term Investments Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments: Carrying value as of (In millions) June 30, 2022 December 31, 2021 Real estate investments $ 1,356 $ 1,152 Securities partnerships 2,499 2,272 Other 252 150 Total $ 4,107 $ 3,574 The gross fair values of our derivative financial instruments are presented in Note 12. As of June 30, 2022 and December 31, 2021, the effects of derivative financial instruments used in these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive loss into Shareholders' net income, amounts excluded from the assessment of hedge effectiveness and fair values of assets posted or held as collateral supporting the fair values of these derivative financial instruments. The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) June 30, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,073 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 1,500 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. As of June 30, 2022 there were no forward contracts denominated in the Taiwan Dollar. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts (1) $ 720 $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts (1) $ 730 $ 720 (1) These instruments are associated with the international life, accident and supplemental benefits businesses that are held for sale and will be unwound, terminated, or otherwise disposed in conjunction with the Chubb Transaction. The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ (71) $ 60 $ (390) $ 70 Credit loss (expense) recoveries (24) (1) (24) (10) Net realized investment gains (losses), before income taxes $ (95) $ 59 $ (414) $ 60

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 12 – Fair Value Measurements The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The following table provides information as of June 30, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 148 $ 147 $ 205 $ 240 $ — $ — $ 353 $ 387 State and local government — — 145 171 — — 145 171 Foreign government — — 2,331 2,611 — 5 2,331 2,616 Corporate — — 10,327 12,606 427 660 10,754 13,266 Mortgage and other asset-backed — — 282 418 85 100 367 518 Total debt securities 148 147 13,290 16,046 512 765 13,950 16,958 Equity securities (1) 9 16 417 160 — 31 426 207 Short-term investments — — 199 428 — — 199 428 Derivative assets — — 258 143 — — 258 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ 54 $ 33 $ — $ — $ 54 $ 33 (1) Excludes certain equity securities that have no readily determinable fair value. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of June 30, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) June 30, 2022 December 31, 2021 Unobservable input June 30, 2022 June 30, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 426 $ 664 Liquidity 60 - 1200 (320) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 85 100 Liquidity 60 - 500 (180) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 512 $ 765 A significant increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement. Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and six months ended June 30, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Six Months Ended (In millions) 2022 2021 2022 2021 Debt and Equity Securities Beginning balance $ 686 $ 903 $ 796 $ 854 Total gains (losses) included in shareholders' net income (2) (1) 10 (11) Gains (losses) included in other comprehensive income (13) 7 (28) (9) Gains (losses) required to adjust future policy benefits for settlement annuities (1) (11) 1 (23) (7) Purchases, sales and settlements Purchases 27 42 76 71 Settlements (71) (9) (152) (25) Total purchases, sales and settlements (44) 33 (76) 46 Transfers into/(out of) Level 3 Transfers into Level 3 17 37 118 123 Transfers out of Level 3 (121) (126) (285) (142) Total transfers into/(out of) Level 3 (104) (89) (167) (19) Ending balance $ 512 $ 854 $ 512 $ 854 Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ (3) $ (1) $ (2) $ (12) Change in unrealized gains or losses included in Other comprehensive income (loss), net of tax for assets held at the end of the reporting period $ (11) $ 7 $ (25) $ (9) (1) Amounts do not accrue to shareholders. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive income (loss), net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income. Separate Accounts The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fair values of Separate account assets at June 30, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 208 $ 227 $ 228 $ 276 $ — $ — $ 436 $ 503 Non-guaranteed separate accounts (1) 212 1,130 6,326 6,406 249 334 6,787 7,870 Subtotal $ 420 $ 1,357 $ 6,554 $ 6,682 $ 249 $ 334 7,223 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 920 842 Total 8,143 9,215 Separate account assets of businesses classified as held for sale (2) (648) (878) Separate account assets per Consolidated Balance Sheets $ 7,495 $ 8,337 (1) Non-guaranteed separate accounts include $4.2 billion as of June 30, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of June 30, 2022 and $0.3 billion as of December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. See Note 5 to the Consolidated Financial Statements for additional information. . Separate account assets classified in Level 3 primarily support Cigna's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three and six months ended June 30, 2022 or 2021. Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of June 30, 2022 Redemption Frequency Redemption Notice (In millions) June 30, 2022 December 31, 2021 Securities partnerships $ 540 $ 513 $ 252 Not applicable Not applicable Real estate funds 376 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 920 $ 842 $ 252 As of June 30, 2022, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception. Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value. For the six months ended June 30, 2022 and 2021, no impairments were recognized requiring these assets to be measured at fair value. Realized investment gains and losses from these observable price changes for the three and six months ended June 30, 2022 and June 30, 2021 were not material. The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at June 30, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy June 30, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,499 $ 1,579 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 30,062 $ 31,526 $ 35,621 $ 31,593

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2022
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest EntitiesWe perform ongoing qualitative analyses of our involvement with variable interest entities to determine if consolidation is required. The Company determined that it was not a primary beneficiary in any material variable interest entity as of June 30, 2022 or December 31, 2021. The Company’s involvement with variable interest entities for which it is not the primary beneficiary has not changed materially from December 31, 2021. For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K. The Company has not provided, and does not intend to provide, financial support to any of these variable interest entities in excess of its maximum exposure.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 14 – Accumulated Other Comprehensive Income (Loss) ("AOCI") AOCI includes net unrealized appreciation (depreciation) on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized. Changes in the components of AOCI were as follows: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Securities and Derivatives Beginning balance $ 125 $ 627 $ 685 $ 900 Appreciation (depreciation) on securities and derivatives (541) 170 (1,246) (172) Tax (expense) benefit 101 (40) 255 25 Net Appreciation (depreciation) on securities and derivatives (440) 130 (991) (147) Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) 38 (11) 27 (6) Reclassification adjustment for tax expense (benefit) included in Shareholders' net income (8) 3 (6) 2 Net (gains) losses reclassified from AOCI to Shareholders' net income 30 (8) 21 (4) Other comprehensive income (loss), net of tax (410) 122 (970) (151) Ending balance $ (285) $ 749 $ (285) $ 749 Translation of foreign currencies Beginning balance $ (294) $ (130) $ (233) $ (15) Translation of foreign currencies (180) 16 (240) (98) Tax (expense) (26) — (29) (5) Other comprehensive income (loss), net of tax (206) 16 (269) (103) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (1) (1) (3) (5) Shareholders' other comprehensive income (loss), net of tax (205) 17 (266) (98) Ending balance $ (499) $ (113) $ (499) $ (113) Postretirement benefits liability Beginning balance $ (1,323) $ (1,728) $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 17 19 33 39 Reclassification adjustment for settlement (Interest expense and other) — 1 — 4 Reclassification adjustment for tax (benefit) included in Shareholders' net income (4) (5) (7) (10) Net adjustments reclassified from AOCI to Shareholders' net income 13 15 26 33 Valuation update 18 — 18 — Tax (expense) (4) — (4) — Net change due to valuation update 14 — 14 — Other comprehensive income (loss), net of tax 27 15 40 33 Ending balance $ (1,296) $ (1,713) $ (1,296) $ (1,713)

Organizational Efficiency Plan

Organizational Efficiency Plan	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Organizational Efficiency Plan	Note 15 – Organizational Efficiency Plan During the fourth quarter of 2021, the Company approved a strategic plan to further leverage its ongoing growth to drive operational efficiency through enhancements to organizational structure and increased use of automation and shared services. As a result, during the fourth quarter of 2021, we recognized a charge in Selling, general and administrative expenses of $168 million, pre-tax ($119 million, after-tax) that included $59 million of one-time expenses related to abandonment of leased assets and impairment of property and equipment as well as $109 million of accrued expenses primarily for severance costs related to headcount reductions. As previously anticipated, during the second quarter of 2022, the Company updated our strategic plan and recognized an additional charge in Selling, general and administrative expenses of $22 million, pre-tax ($17 million, after-tax) related to accrued expenses primarily for severance costs. The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (37) Second quarter 2022 charge 22 Balance, June 30, 2022 $ 88 We expect most of the accrued liability to be paid by the end of 2023.

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) June 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 445 $ 478 Accrued expenses and other liabilities $ 151 $ 159 Other non-current liabilities 391 436 Total operating lease liabilities $ 542 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (63) (51) Property and equipment, net $ 55 $ 50 Short-term debt $ 23 $ 23 Long-term debt 35 28 Total finance lease liabilities $ 58 $ 51 (1) Operating leases include $28 million as of June 30, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $22 million as of June 30, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.
Leases	Note 16 – Leases Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) June 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 445 $ 478 Accrued expenses and other liabilities $ 151 $ 159 Other non-current liabilities 391 436 Total operating lease liabilities $ 542 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (63) (51) Property and equipment, net $ 55 $ 50 Short-term debt $ 23 $ 23 Long-term debt 35 28 Total finance lease liabilities $ 58 $ 51 (1) Operating leases include $28 million as of June 30, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $22 million as of June 30, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 17 – Income Taxes Income Tax Expense The 20.8% effective tax rate for the three months ended June 30, 2022 and the 21.6% effective tax rate for the six months ended June 30, 2022 were lower than the 22.2% rate for the three months ended June 30, 2021 and the 22.4% rate for the six months ended June 30, 2021. These decreases are primarily attributable to favorable results relative to our foreign operations and for the six months ended June 30, 2022 the favorable impact of the remeasurement of deferred taxes, partially offset by the absence of the favorable impact of non-recurring items recorded in 2021.

Contingencies and Other Matters

Contingencies and Other Matters	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 18 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A. Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of June 30, 2022, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $430 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of June 30, 2022. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B. Certain Other Guarantees The Company had indemnification obligations as of June 30, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of June 30, 2022. C. Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the six months ended June 30, 2022. D. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation. Litigation Matters Express Scripts Litigation with Elevance . In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claims it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations. On June 10, 2022, Express Scripts filed a Motion for Partial Summary Judgment seeking to limit Elevance’s remaining prior authorization claims and a Motion to Exclude certain opinions offered by its experts. Elevance filed its opposition to both motions, and a cross-motion to submit a supplemental expert report, on July 9, 2022. Express Scripts’ pending Motions were fully briefed by the end of July 2022. Medicare Advantage. A qui tam action that was filed by a private individual on behalf of the government in the United States District Court for the Southern District of New York in 2017 was unsealed on August 6, 2020. The action asserts claims related to risk adjustment practices arising from certain health exams conducted as part of the Company's Medicare Advantage business. In September 2021, the qui tam action was transferred to the United States District Court for the Middle District of Tennessee. On January 11, 2022, the U.S. Department of Justice ("DOJ") (U.S. Attorney's Offices for the Southern District of New York and the Middle District of Tennessee) filed a motion to partially intervene, which is pending before the court. The Company has opposed the DOJ's motion to intervene and the government filed its reply brief on February 1, 2022. The motion has been fully briefed and is under the court's review. Regulatory Matters Civil Investigative Demand . The DOJ is conducting industry-wide investigations of Medicare Advantage organizations' risk adjustment practices. For certain Medicare Advantage organizations, including Cigna, those investigations have resulted in litigation (see "Litigation Matters—Medicare Advantage" above). The Company is currently responding to information requests (civil investigative demands) from the DOJ (U.S. Attorney's Office for the Eastern District of Pennsylvania). The Company is cooperating with the DOJ and has responded and continues to respond to its requests.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	Note 19 – Segment Information See Note 1 for a description of our segments, including the segment change effective in the fourth quarter of 2021. Prior year segment information has been adjusted to reflect the segment change and a description of our basis of reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy-related transactions between the Evernorth and Cigna Healthcare segments. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income/loss attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance. The following tables present the special items recorded by the Company for the three and six months ended June 30, 2022 and 2021: Three Months Ended Six Months Ended (In millions) June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Integration and transaction-related costs $ 26 $ 36 $ 14 $ 16 $ 63 $ 88 $ 36 $ 45 Charge for organizational efficiency plan 17 22 — — 17 22 — — Charges (benefits) associated with litigation matters (20) (28) — — (20) (28) (21) (27) Debt extinguishment costs — — 9 10 — — 110 141 Total impact from special items $ 23 $ 30 $ 23 $ 26 $ 60 $ 82 $ 125 $ 159 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended June 30, 2022 Revenues from external customers $ 33,716 $ 10,622 $ 817 $ — $ 45,155 Intersegment revenues 1,131 586 — (1,717) Net investment income 16 178 131 — 325 Total revenues 34,863 11,386 948 (1,717) 45,480 Net realized investment results from certain equity method investments — (49) — — (49) Adjusted revenues $ 34,863 $ 11,337 $ 948 $ (1,717) $ 45,431 Income (loss) before income taxes $ 1,044 $ 1,205 $ 167 $ (431) $ 1,985 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (13) — (2) — (15) Net realized investment (gains) losses (1) — (22) 68 — 46 Amortization of acquired intangible assets 444 57 — — 501 Special items Integration and transaction-related costs — — — 36 36 Charge for organizational efficiency plan — — — 22 22 Charges (benefits) associated with litigation matters — — — (28) (28) Pre-tax adjusted income (loss) from operations $ 1,475 $ 1,240 $ 233 $ (401) $ 2,547 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended June 30, 2021 Revenues from external customers $ 31,553 $ 10,403 $ 865 $ — $ 42,821 Intersegment revenues 1,034 590 — (1,624) Net investment income 5 180 125 — 310 Total revenues 32,592 11,173 990 (1,624) 43,131 Net realized investment results from certain equity method investments — (24) — — (24) Adjusted revenues $ 32,592 $ 11,149 $ 990 $ (1,624) $ 43,107 Income (loss) before income taxes $ 929 $ 1,111 $ 228 $ (370) $ 1,898 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (6) — (5) — (11) Net realized investment (gains) losses (1) 2 (74) (11) — (83) Amortization of acquired intangible assets 488 12 3 — 503 Special items Integration and transaction-related costs — — — 16 16 Debt extinguishment costs — — — 10 10 Pre-tax adjusted income (loss) from operations $ 1,413 $ 1,049 $ 215 $ (344) $ 2,333 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Six months ended June 30, 2022 Revenues from external customers $ 66,005 $ 21,083 $ 1,658 $ — $ 88,746 Intersegment revenues 2,418 1,148 — (3,566) Net investment income 26 444 269 — 739 Total revenues 68,449 22,675 1,927 (3,566) 89,485 Net realized investment results from certain equity method investments — 54 — — 54 Adjusted revenues $ 68,449 $ 22,729 $ 1,927 $ (3,566) $ 89,539 Income (loss) before income taxes $ 1,914 $ 2,064 $ 382 $ (826) $ 3,534 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (24) (1) (7) — (32) Net realized investment (gains) losses (1) — 384 84 — 468 Amortization of acquired intangible assets 887 72 — — 959 Special items Integration and transaction-related costs — — — 88 88 Charge for organizational efficiency plan — — — 22 22 Charges (benefits) associated with litigation matters — — — (28) (28) Pre-tax adjusted income (loss) from operations $ 2,777 $ 2,519 $ 459 $ (744) $ 5,011 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Six months ended June 30, 2021 Revenues from external customers $ 60,972 $ 20,688 $ 1,741 $ — $ 83,401 Intersegment revenues 2,232 1,099 — (3,331) Net investment income 8 439 254 — 701 Total revenues 63,212 22,226 1,995 (3,331) 84,102 Net realized investment results from certain equity method investments — (10) — — (10) Adjusted revenues $ 63,212 $ 22,216 $ 1,995 $ (3,331) $ 84,092 Income (loss) before income taxes $ 1,678 $ 2,156 $ 434 $ (857) $ 3,411 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (11) — (23) Net realized investment (gains) losses (1) 4 (90) 16 — (70) Amortization of acquired intangible assets 965 26 7 — 998 Special items Integration and transaction-related costs — — — 45 45 Charges (benefits) associated with litigation matters — — — (27) (27) Debt extinguishment costs — — — 141 141 Pre-tax adjusted income (loss) from operations $ 2,636 $ 2,091 $ 446 $ (698) $ 4,475 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 16,107 $ 16,166 $ 31,638 $ 31,304 Home delivery and specialty revenues 15,268 13,341 29,967 26,115 Other revenues 1,667 1,619 3,379 3,007 Intercompany eliminations (1,070) (1,079) (2,315) (2,354) Total pharmacy revenues 31,972 30,047 62,669 58,072 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,771 3,578 7,491 7,101 Stop loss 1,344 1,194 2,669 2,388 Other 352 308 712 618 U.S. Government Medicare Advantage 2,053 2,116 4,131 4,208 Medicare Part D 345 410 746 860 Other 1,038 1,227 1,978 2,365 International Health 712 633 1,414 1,274 Total Cigna Healthcare 9,615 9,466 19,141 18,814 International businesses held for sale 737 809 1,500 1,618 Other 74 50 143 108 Intercompany eliminations — (2) (2) (3) Total premiums 10,426 10,323 20,782 20,537 Services (Fees) (ASC 606) Evernorth 1,790 1,456 3,414 2,770 Cigna Healthcare 1,478 1,425 2,974 2,859 Other Operations 4 5 9 10 Other revenues 132 108 147 127 Intercompany eliminations (647) (543) (1,249) (974) Total fees and other revenues 2,757 2,451 5,295 4,792 Total revenues from external customers $ 45,155 $ 42,821 $ 88,746 $ 83,401

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements There were no new accounting standards adopted as of June 30, 2022 that had a material impact on our financial statements. There are no accounting pronouncements not yet adopted, with the exception of Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Insurance Contracts ("LDTI") that are expected to impact Cigna's operations or our financial statements. Refer to the Company's 2021 Form 10-K for discussion of the LDTI standard and related expected effects to Cigna. We continue to make progress on our LDTI implementation plan and are on track for the January 1, 2023 adoption date. In July 2022, the Financial Accounting Standards Board ("FASB") issued a proposed standard for comment that would simplify the retrospective adoption of LDTI. The proposal would permit companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. If the FASB approves the proposed standard, Cigna expects to make this policy election for the contracts sold in the Chubb Transaction.
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. This liability includes amounts from the International Health businesses now reported in Cigna Healthcare following our change in segment reporting in 2021. The prior year roll forward has been updated to reflect this segment change.
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 for additional information on reinsuranceThe Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2021 Form 10-K.
Investments	Cigna's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments.Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2021 Form 10-K. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
Derivative Financial Instruments	The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company has written and purchased GMIB reinsurance contracts in its run-off reinsurance business that are accounted for as freestanding derivatives as discussed in Note 10. Derivatives in the Company's separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate account policyholders. Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. As of June 30, 2022 there were no forward contracts denominated in the Taiwan Dollar. Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments.
Fair Value Measurements	The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive income (loss), net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Variable Interest Entities	For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2021 Form 10-K.
Separate Accounts	Separate Accounts The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.
AOCI	AOCI includes net unrealized appreciation (depreciation) on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (see Note 11), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of June 30, 2022 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.Guaranty Fund AssessmentsThe Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.
Commitment and Contingencies	The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accruals for the matters discussed below under "Litigation Matters" and "Regulatory Matters" are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation.
Segment Information	Intersegment revenues primarily reflect pharmacy-related transactions between the Evernorth and Cigna Healthcare segments.The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income/loss attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.
Revenues and Costs	Evernorth may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Accounts Receivable, Net	The following amounts were included within Accounts receivable, net: (In millions) June 30, 2022 December 31, 2021 Noninsurance customer receivables $ 7,578 $ 6,274 Pharmaceutical manufacturers receivables 7,006 5,463 Insurance customer receivables 2,790 2,932 Other receivables 952 456 Total 18,326 15,125 Accounts receivable, net classified as Assets of businesses held for sale (36) (54) Accounts receivable, net per Consolidated Balance Sheets $ 18,290 $ 15,071

Assets and Liabilities of Bus_2

Assets and Liabilities of Businesses Held for Sale (Tables)	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Business Held for Sale	The assets and liabilities of businesses held for sale were as follows: (In millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 455 $ 406 Investments 4,518 5,109 Deferred policy acquisition costs 2,598 2,755 Separate account assets 648 878 Goodwill, other intangible assets and all other assets 833 909 Total assets of businesses held for sale 9,052 10,057 Insurance and contractholder liabilities 4,427 4,644 Accounts payable, accrued expenses and other liabilities 420 452 Deferred tax liabilities, net 356 449 Separate account liabilities 648 878 Total liabilities of businesses held for sale $ 5,851 $ 6,423

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share were computed as follows: Three Months Ended June 30, 2022 June 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,559 $ 1,559 $ 1,467 $ 1,467 Shares: Weighted average 315,122 315,122 341,479 341,479 Common stock equivalents 3,182 3,182 3,450 3,450 Total shares 315,122 3,182 318,304 341,479 3,450 344,929 EPS $ 4.95 $ (0.05) $ 4.90 $ 4.30 $ (0.05) $ 4.25 Six Months Ended June 30, 2022 June 30, 2021 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 2,742 $ 2,742 $ 2,628 $ 2,628 Shares: Weighted average 316,795 316,795 344,845 344,845 Common stock equivalents 2,989 2,989 3,589 3,589 Total shares 316,795 2,989 319,784 344,845 3,589 348,434 EPS $ 8.66 $ (0.09) $ 8.57 $ 7.62 $ (0.08) $ 7.54
Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share	The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Anti-dilutive options 1.3 1.5 2.0 1.5

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Outstanding Amounts of Debt and Finance Leases	The outstanding amounts of debt and finance leases were as follows: (In millions) June 30, 2022 December 31, 2021 Short-term debt Commercial paper $ 1,797 $ 2,027 $500 million, 3.05% Notes due 11/2022 497 495 $17 million, 8.3% Notes due 1/2023 17 — $63 million, 7.65% Notes due 3/2023 63 — Other, including finance leases 23 23 Total short-term debt $ 2,397 $ 2,545 Long-term debt $17 million, 8.3% Notes due 2023 $ — $ 17 $63 million, 7.65% Notes due 2023 — 63 $700 million, Floating Rate Notes due 2023 699 699 $1,000 million, 3% Notes due 2023 989 985 $1,187 million, 3.75% Notes due 2023 1,186 1,185 $500 million, 0.613% Notes due 2024 499 498 $1,000 million, 3.5% Notes due 2024 987 983 $900 million, 3.25% Notes due 2025 (1) 895 897 $2,200 million, 4.125% Notes due 2025 2,194 2,193 $1,500 million, 4.5% Notes due 2026 1,503 1,504 $800 million, 1.25% Notes due 2026 797 796 $1,500 million, 3.4% Notes due 2027 1,429 1,423 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 596 $3,800 million, 4.375% Notes due 2028 3,783 3,782 $1,500 million, 2.4% Notes due 2030 1,491 1,490 $1,500 million, 2.375% Notes due 2031 (1) 1,414 1,500 $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 2,192 2,192 $750 million, 3.2% Notes due 2040 743 743 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 489 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,466 1,465 $1,000 million, 3.875% Notes due 2047 989 988 $3,000 million, 4.9% Notes due 2048 2,968 2,967 $1,250 million, 3.4% Notes due 2050 1,236 1,236 $1,500 million, 3.4% Notes due 2051 1,476 1,477 Other, including finance leases 35 28 Total long-term debt $ 30,984 $ 31,125 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 for further information about the Company's interest rate risk management and these derivative instruments.

Common and Preferred Stock (Tab

Common and Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Dividend Payments	The following table provides details of Cigna's dividend payments for the six months ended June 30: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2022 March 9, 2022 March 24, 2022 $1.12 $357 June 8, 2022 June 23, 2022 $1.12 $352 2021 March 10, 2021 March 25, 2021 $1.00 $345 June 8, 2021 June 23, 2021 $1.00 $342

Insurance and Contractholder _2

Insurance and Contractholder Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Insurance Loss Reserves [Abstract]
Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses	The Company's insurance and contractholder liabilities were comprised of the following: June 30, 2022 December 31, 2021 June 30, 2021 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 371 $ 6,606 $ 6,977 $ 352 $ 6,702 $ 7,054 $ 7,122 Future policy benefits 246 8,454 8,700 312 9,194 9,506 9,531 Unearned premiums 575 415 990 558 418 976 912 Unpaid claims and claim expenses Cigna Healthcare 4,432 58 4,490 4,159 102 4,261 4,228 Other Operations 506 195 701 548 180 728 722 Total 6,130 15,728 21,858 5,929 16,596 22,525 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (476) (3,951) (4,427) (611) (4,033) (4,644) Total insurance and contractholder liabilities $ 5,654 $ 11,777 $ 17,431 $ 5,318 $ 12,563 $ 17,881 $ 22,515 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.6 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of June 30, 2022 and $3.8 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of December 31, 2021. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment for the six months ended June 30 was as follows: Six Months Ended (In millions) June 30, 2022 June 30, 2021 Beginning balance $ 4,261 $ 3,695 Less: Reinsurance and other amounts recoverable 261 237 Beginning balance, net 4,000 3,458 Incurred costs related to: Current year 15,751 15,716 Prior years (268) (228) Total incurred 15,483 15,488 Paid costs related to: Current year 11,900 12,065 Prior years 3,290 2,858 Total paid 15,190 14,923 Ending balance, net 4,293 4,023 Add: Reinsurance and other amounts recoverable 197 205 Ending balance $ 4,490 $ 4,228 Liability balance details. The liability details for unpaid claims and claim expenses are as follows. The liability balance no longer includes the International Health businesses now reported in Cigna Healthcare following our change in segment reporting. The prior year roll forward has been updated to reflect the segment change. (In millions) June 30, 2022 June 30, 2021 Other Operations International businesses held for sale and our interest in a joint venture in Türkiye $ 412 $ 438 Other Operations 289 284 Unpaid claims and claim expenses - Other Operations $ 701 $ 722 Activity in the unpaid claims and claim expenses for international businesses held for sale and our interest in a joint venture in Türkiye is presented in the following table. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been largely reinsured. Six Months Ended (In millions) June 30, 2022 (1) June 30, 2021 Beginning balance $ 447 $ 452 Less: Reinsurance 46 45 Beginning balance, net 401 407 Incurred claims related to: Current year 490 501 Prior years 4 (4) Total incurred 494 497 Paid claims related to: Current year 306 314 Prior years 187 181 Total paid 493 495 Foreign currency (28) (16) Ending balance, net 374 393 Add: Reinsurance 38 45 Ending balance $ 412 $ 438
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses	Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions for the six months ended June 30 were as follows: Six Months Ended (Dollars in millions) June 30, 2022 June 30, 2021 $ % (1) $ % (2) Actual completion factors $ 84 0.2 % $ 92 0.3 % Medical cost trend 184 0.6 136 0.5 Total favorable variance $ 268 0.8 % $ 228 0.8 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2021. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2020.

Reinsurance (Tables)

Reinsurance (Tables)	6 Months Ended
	Jun. 30, 2022
Reinsurance Disclosures [Abstract]
Reinsurance Recoverables by Range of External Credit Rating and Collateral Level	The Company's reinsurance recoverables as of June 30, 2022 are presented in the following table by range of external credit rating and collateral level: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 173 $ 173 BBB- to BBB+ equivalent current credit ratings (1) — — 61 61 Not rated 125 4 43 172 Total recoverables related to ongoing operations (2) 125 4 277 406 Acquisition, disposition or run-off activities A- equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,870 — 2,870 Berkshire Hathaway Life Insurance Company of Nebraska 260 428 — 688 Prudential Retirement Insurance and Annuity (marketed under Empower brand) 140 — — 140 Prudential Insurance Company of America 394 — — 394 Life Insurance Company of North America — 401 — 401 Other 208 19 16 243 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or run-off activities 1,002 3,731 19 4,752 Total $ 1,127 $ 3,735 $ 296 $ 5,158 Allowance for uncollectible reinsurance (30) Total reinsurance recoverables (2) $ 5,128 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $164 million of current reinsurance recoverables that are reported in Other current assets and $90 million of recoverables classified as Assets of businesses held for sale as of June 30, 2022. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death	The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) June 30, 2022 December 31, 2021 Account value $ 7,626 $ 9,795 Net amount at risk $ 2,264 $ 1,392 Number of contractholders (estimated) 160,000 170,000
Schedule of Derivative Assets at Fair Value	GMIB liabilities totaling $463 million as of June 30, 2022 and $572 million as of December 31, 2021 are classified as Level 3 because fair value inputs are largely unobservable. The GMIB liabilities reflect the Company's credit risk, while the reinsurance recoverable reflects the credit risk of the reinsurers. There were three reinsurers covering 100% of the GMIB exposures as of June 30, 2022 and December 31, 2021 as follows: (In millions) Line of Business Reinsurer June 30, 2022 December 31, 2021 Collateral and Other Terms at June 30, 2022 GMIB Berkshire $ 230 $ 283 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 136 167 Liberty Re (Bermuda) Ltd. 123 151 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 489 $ 601 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Investments [Abstract]
Investments by category and current or long-term classification	The following table summarizes the Company's investments by category and current or long-term classification: June 30, 2022 December 31, 2021 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 784 $ 13,166 $ 13,950 $ 796 $ 16,162 $ 16,958 Equity securities 69 767 836 — 603 603 Commercial mortgage loans 13 1,566 1,579 40 1,526 1,566 Policy loans — 1,325 1,325 — 1,338 1,338 Other long-term investments — 4,107 4,107 — 3,574 3,574 Short-term investments 199 — 199 428 — 428 Total 1,065 20,931 21,996 1,264 23,203 24,467 Investments classified as assets of businesses held for sale (1) (311) (4,207) (4,518) (344) (4,765) (5,109) Investments per Consolidated Balance Sheets $ 754 $ 16,724 $ 17,478 $ 920 $ 18,438 $ 19,358
Debt Securities by Contractual Maturity	The amortized cost and fair value by contractual maturity periods for debt securities were as follows at June 30, 2022: (In millions) Amortized Fair Due in one year or less $ 820 $ 813 Due after one year through five years 4,655 4,454 Due after five years through ten years 4,844 4,407 Due after ten years 4,206 3,909 Mortgage and other asset-backed securities 399 367 Total $ 14,924 $ 13,950
Gross Unrealized Appreciation (Depreciation) on Debt Securities	Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair June 30, 2022 Federal government and agency $ 303 $ — $ 56 $ (6) $ 353 State and local government 157 — — (12) 145 Foreign government 2,471 — 63 (203) 2,331 Corporate 11,594 (45) 151 (946) 10,754 Mortgage and other asset-backed 399 — 2 (34) 367 Total $ 14,924 $ (45) $ 272 $ (1,201) $ 13,950 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,266 $ (5) $ 220 $ (185) $ 2,296 December 31, 2021 Federal government and agency $ 287 $ — $ 101 $ (1) $ 387 State and local government 154 — 17 — 171 Foreign government 2,468 — 194 (46) 2,616 Corporate 12,361 (23) 1,008 (80) 13,266 Mortgage and other asset-backed 505 — 17 (4) 518 Total $ 15,775 $ (23) $ 1,337 $ (131) $ 16,958 Investments supporting liabilities of the Company's run-off settlement annuity business (included in total above) (1) $ 2,262 $ (5) $ 720 $ (10) $ 2,967 (1) Net unrealized appreciation for these investments is excluded from Accumulated other comprehensive loss.
Summary of Debt Securities with a Decline in Fair Value	The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of June 30, 2022 and December 31, 2021. June 30, 2022 December 31, 2021 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 8,378 $ 9,258 $ (880) 2,695 $ 2,785 $ 2,861 $ (76) 909 Below investment grade 1,124 1,252 (128) 1,405 561 578 (17) 781 More than one year Investment grade 750 916 (166) 355 382 412 (30) 143 Below investment grade 191 218 (27) 134 162 170 (8) 53 Total $ 10,443 $ 11,644 $ (1,201) 4,589 $ 3,890 $ 4,021 $ (131) 1,886
Equity Security Investments	The following table provides the values of the Company's equity security investments as of June 30, 2022 and December 31, 2021: June 30, 2022 December 31, 2021 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 831 $ 426 $ 257 $ 207 Equity securities with no readily determinable fair value 283 410 270 396 Total $ 1,114 $ 836 $ 527 $ 603
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio	The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio as of June 30, 2022 and December 31, 2021: (Dollars in millions) June 30, 2022 December 31, 2021 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 850 2.21 $ 560 2.18 60% to 79% 567 1.49 883 1.89 80% to 100% 108 1.21 129 1.47 Greater than 100% 63 1.04 — — Allowance for credit losses (9) (6) Total $ 1,579 1.84 59 % $ 1,566 1.96 61 %
Carrying Value Information for Other Long-Term Investments	The following table provides the carrying value information for these investments: Carrying value as of (In millions) June 30, 2022 December 31, 2021 Real estate investments $ 1,356 $ 1,152 Securities partnerships 2,499 2,272 Other 252 150 Total $ 4,107 $ 3,574
Summary of Derivative Instruments Held	As of June 30, 2022 and December 31, 2021, the effects of derivative financial instruments used in these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive loss into Shareholders' net income, amounts excluded from the assessment of hedge effectiveness and fair values of assets posted or held as collateral supporting the fair values of these derivative financial instruments. The following table summarizes the types and notional quantity of derivative instruments held by the Company: Notional Value as of (In millions) June 30, 2022 December 31, 2021 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Foreign currency swap contracts $ 1,073 $ 1,081 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 1,500 $ 750 Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros, while foreign currency forward contracts are primarily denominated in Korean Won, with the remaining instruments denominated in New Zealand Dollars and Taiwan Dollars. As of June 30, 2022 there were no forward contracts denominated in the Taiwan Dollar. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts (1) $ 720 $ 1,380 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company's foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts (1) $ 730 $ 720 (1) These instruments are associated with the international life, accident and supplemental benefits businesses that are held for sale and will be unwound, terminated, or otherwise disposed in conjunction with the Chubb Transaction.
Realized Gains and Losses on Investments	The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ (71) $ 60 $ (390) $ 70 Credit loss (expense) recoveries (24) (1) (24) (10) Net realized investment gains (losses), before income taxes $ (95) $ 59 $ (414) $ 60

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Financial Liabilities Carried at Fair Value	The following table provides information as of June 30, 2022 and December 31, 2021 about the Company's financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 As of June 30, 2022 As of December 31, 2021 Financial assets at fair value Debt securities Federal government and agency $ 148 $ 147 $ 205 $ 240 $ — $ — $ 353 $ 387 State and local government — — 145 171 — — 145 171 Foreign government — — 2,331 2,611 — 5 2,331 2,616 Corporate — — 10,327 12,606 427 660 10,754 13,266 Mortgage and other asset-backed — — 282 418 85 100 367 518 Total debt securities 148 147 13,290 16,046 512 765 13,950 16,958 Equity securities (1) 9 16 417 160 — 31 426 207 Short-term investments — — 199 428 — — 199 428 Derivative assets — — 258 143 — — 258 143 Financial liabilities at fair value Derivative liabilities $ — $ — $ 54 $ 33 $ — $ — $ 54 $ 33
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities	The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of June 30, 2022 and December 31, 2021. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) June 30, 2022 December 31, 2021 Unobservable input June 30, 2022 June 30, 2022 December 31, 2021 Debt securities Corporate and government debt securities $ 426 $ 664 Liquidity 60 - 1200 (320) bps 60 - 1060 (410) bps Mortgage and other asset-backed securities 85 100 Liquidity 60 - 500 (180) bps 60 - 390 (100) bps Other debt securities 1 1 Total Level 3 debt securities $ 512 $ 765
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value	The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and six months ended June 30, 2022 and 2021. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Six Months Ended (In millions) 2022 2021 2022 2021 Debt and Equity Securities Beginning balance $ 686 $ 903 $ 796 $ 854 Total gains (losses) included in shareholders' net income (2) (1) 10 (11) Gains (losses) included in other comprehensive income (13) 7 (28) (9) Gains (losses) required to adjust future policy benefits for settlement annuities (1) (11) 1 (23) (7) Purchases, sales and settlements Purchases 27 42 76 71 Settlements (71) (9) (152) (25) Total purchases, sales and settlements (44) 33 (76) 46 Transfers into/(out of) Level 3 Transfers into Level 3 17 37 118 123 Transfers out of Level 3 (121) (126) (285) (142) Total transfers into/(out of) Level 3 (104) (89) (167) (19) Ending balance $ 512 $ 854 $ 512 $ 854 Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date $ (3) $ (1) $ (2) $ (12) Change in unrealized gains or losses included in Other comprehensive income (loss), net of tax for assets held at the end of the reporting period $ (11) $ 7 $ (25) $ (9) (1) Amounts do not accrue to shareholders.
Fair Values of Separate Account Assets	Fair values of Separate account assets at June 30, 2022 and December 31, 2021 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 Guaranteed separate accounts (See Note 18) $ 208 $ 227 $ 228 $ 276 $ — $ — $ 436 $ 503 Non-guaranteed separate accounts (1) 212 1,130 6,326 6,406 249 334 6,787 7,870 Subtotal $ 420 $ 1,357 $ 6,554 $ 6,682 $ 249 $ 334 7,223 8,373 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 920 842 Total 8,143 9,215 Separate account assets of businesses classified as held for sale (2) (648) (878) Separate account assets per Consolidated Balance Sheets $ 7,495 $ 8,337 (1) Non-guaranteed separate accounts include $4.2 billion as of June 30, 2022 and $4.5 billion as of December 31, 2021 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of June 30, 2022 and $0.3 billion as of December 31, 2021. (2) Investments related to the international life, accident and supplemental benefits businesses that are held for sale. See Note 5 to the Consolidated Financial Statements for additional information.
Additional Information on Separate Account Assets Priced at NAV	Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of June 30, 2022 Redemption Frequency Redemption Notice (In millions) June 30, 2022 December 31, 2021 Securities partnerships $ 540 $ 513 $ 252 Not applicable Not applicable Real estate funds 376 325 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 920 $ 842 $ 252
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value	The following table includes the Company's financial instruments not recorded at fair value, however fair value disclosure is required at June 30, 2022 and December 31, 2021. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy June 30, 2022 December 31, 2021 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,499 $ 1,579 $ 1,598 $ 1,566 Long-term debt, including current maturities, excluding finance leases Level 2 $ 30,062 $ 31,526 $ 35,621 $ 31,593

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in the Components of AOCI	Changes in the components of AOCI were as follows: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Securities and Derivatives Beginning balance $ 125 $ 627 $ 685 $ 900 Appreciation (depreciation) on securities and derivatives (541) 170 (1,246) (172) Tax (expense) benefit 101 (40) 255 25 Net Appreciation (depreciation) on securities and derivatives (440) 130 (991) (147) Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) 38 (11) 27 (6) Reclassification adjustment for tax expense (benefit) included in Shareholders' net income (8) 3 (6) 2 Net (gains) losses reclassified from AOCI to Shareholders' net income 30 (8) 21 (4) Other comprehensive income (loss), net of tax (410) 122 (970) (151) Ending balance $ (285) $ 749 $ (285) $ 749 Translation of foreign currencies Beginning balance $ (294) $ (130) $ (233) $ (15) Translation of foreign currencies (180) 16 (240) (98) Tax (expense) (26) — (29) (5) Other comprehensive income (loss), net of tax (206) 16 (269) (103) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (1) (1) (3) (5) Shareholders' other comprehensive income (loss), net of tax (205) 17 (266) (98) Ending balance $ (499) $ (113) $ (499) $ (113) Postretirement benefits liability Beginning balance $ (1,323) $ (1,728) $ (1,336) $ (1,746) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 17 19 33 39 Reclassification adjustment for settlement (Interest expense and other) — 1 — 4 Reclassification adjustment for tax (benefit) included in Shareholders' net income (4) (5) (7) (10) Net adjustments reclassified from AOCI to Shareholders' net income 13 15 26 33 Valuation update 18 — 18 — Tax (expense) (4) — (4) — Net change due to valuation update 14 — 14 — Other comprehensive income (loss), net of tax 27 15 40 33 Ending balance $ (1,296) $ (1,713) $ (1,296) $ (1,713)

Organizational Efficiency Plan

Organizational Efficiency Plan (Tables)	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Rollforward of Accrued Liability	The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities: (In millions) Balance, December 31, 2021 $ 103 2022 payments (37) Second quarter 2022 charge 22 Balance, June 30, 2022 $ 88

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities	Operating and finance lease right-of-use ("ROU") assets and lease liabilities were as follows: (In millions) June 30, 2022 December 31, 2021 Operating leases: (1) Operating lease ROU assets in Other assets $ 445 $ 478 Accrued expenses and other liabilities $ 151 $ 159 Other non-current liabilities 391 436 Total operating lease liabilities $ 542 $ 595 Finance leases: Property and equipment, gross $ 118 $ 101 Accumulated depreciation (63) (51) Property and equipment, net $ 55 $ 50 Short-term debt $ 23 $ 23 Long-term debt 35 28 Total finance lease liabilities $ 58 $ 51 (1) Operating leases include $28 million as of June 30, 2022 and $27 million as of December 31, 2021 classified as Assets of businesses held for sale and $22 million as of June 30, 2022, and $28 million as of December 31, 2021 classified as Liabilities of businesses held for sale.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Summary of Special Items	The following tables present the special items recorded by the Company for the three and six months ended June 30, 2022 and 2021: Three Months Ended Six Months Ended (In millions) June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Integration and transaction-related costs $ 26 $ 36 $ 14 $ 16 $ 63 $ 88 $ 36 $ 45 Charge for organizational efficiency plan 17 22 — — 17 22 — — Charges (benefits) associated with litigation matters (20) (28) — — (20) (28) (21) (27) Debt extinguishment costs — — 9 10 — — 110 141 Total impact from special items $ 23 $ 30 $ 23 $ 26 $ 60 $ 82 $ 125 $ 159
Summarized Segment Financial Information	Summarized segment financial information was as follows: (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended June 30, 2022 Revenues from external customers $ 33,716 $ 10,622 $ 817 $ — $ 45,155 Intersegment revenues 1,131 586 — (1,717) Net investment income 16 178 131 — 325 Total revenues 34,863 11,386 948 (1,717) 45,480 Net realized investment results from certain equity method investments — (49) — — (49) Adjusted revenues $ 34,863 $ 11,337 $ 948 $ (1,717) $ 45,431 Income (loss) before income taxes $ 1,044 $ 1,205 $ 167 $ (431) $ 1,985 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (13) — (2) — (15) Net realized investment (gains) losses (1) — (22) 68 — 46 Amortization of acquired intangible assets 444 57 — — 501 Special items Integration and transaction-related costs — — — 36 36 Charge for organizational efficiency plan — — — 22 22 Charges (benefits) associated with litigation matters — — — (28) (28) Pre-tax adjusted income (loss) from operations $ 1,475 $ 1,240 $ 233 $ (401) $ 2,547 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended June 30, 2021 Revenues from external customers $ 31,553 $ 10,403 $ 865 $ — $ 42,821 Intersegment revenues 1,034 590 — (1,624) Net investment income 5 180 125 — 310 Total revenues 32,592 11,173 990 (1,624) 43,131 Net realized investment results from certain equity method investments — (24) — — (24) Adjusted revenues $ 32,592 $ 11,149 $ 990 $ (1,624) $ 43,107 Income (loss) before income taxes $ 929 $ 1,111 $ 228 $ (370) $ 1,898 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (6) — (5) — (11) Net realized investment (gains) losses (1) 2 (74) (11) — (83) Amortization of acquired intangible assets 488 12 3 — 503 Special items Integration and transaction-related costs — — — 16 16 Debt extinguishment costs — — — 10 10 Pre-tax adjusted income (loss) from operations $ 1,413 $ 1,049 $ 215 $ (344) $ 2,333 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Six months ended June 30, 2022 Revenues from external customers $ 66,005 $ 21,083 $ 1,658 $ — $ 88,746 Intersegment revenues 2,418 1,148 — (3,566) Net investment income 26 444 269 — 739 Total revenues 68,449 22,675 1,927 (3,566) 89,485 Net realized investment results from certain equity method investments — 54 — — 54 Adjusted revenues $ 68,449 $ 22,729 $ 1,927 $ (3,566) $ 89,539 Income (loss) before income taxes $ 1,914 $ 2,064 $ 382 $ (826) $ 3,534 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (24) (1) (7) — (32) Net realized investment (gains) losses (1) — 384 84 — 468 Amortization of acquired intangible assets 887 72 — — 959 Special items Integration and transaction-related costs — — — 88 88 Charge for organizational efficiency plan — — — 22 22 Charges (benefits) associated with litigation matters — — — (28) (28) Pre-tax adjusted income (loss) from operations $ 2,777 $ 2,519 $ 459 $ (744) $ 5,011 (In millions) Evernorth Cigna Healthcare Other Operations Corporate and Eliminations Total Six months ended June 30, 2021 Revenues from external customers $ 60,972 $ 20,688 $ 1,741 $ — $ 83,401 Intersegment revenues 2,232 1,099 — (3,331) Net investment income 8 439 254 — 701 Total revenues 63,212 22,226 1,995 (3,331) 84,102 Net realized investment results from certain equity method investments — (10) — — (10) Adjusted revenues $ 63,212 $ 22,216 $ 1,995 $ (3,331) $ 84,092 Income (loss) before income taxes $ 1,678 $ 2,156 $ 434 $ (857) $ 3,411 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (11) — (23) Net realized investment (gains) losses (1) 4 (90) 16 — (70) Amortization of acquired intangible assets 965 26 7 — 998 Special items Integration and transaction-related costs — — — 45 45 Charges (benefits) associated with litigation matters — — — (27) (27) Debt extinguishment costs — — — 141 141 Pre-tax adjusted income (loss) from operations $ 2,636 $ 2,091 $ 446 $ (698) $ 4,475
Revenue from External Customers	Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2022 2021 2022 2021 Products (Pharmacy revenues) (ASC 606) Network revenues $ 16,107 $ 16,166 $ 31,638 $ 31,304 Home delivery and specialty revenues 15,268 13,341 29,967 26,115 Other revenues 1,667 1,619 3,379 3,007 Intercompany eliminations (1,070) (1,079) (2,315) (2,354) Total pharmacy revenues 31,972 30,047 62,669 58,072 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 3,771 3,578 7,491 7,101 Stop loss 1,344 1,194 2,669 2,388 Other 352 308 712 618 U.S. Government Medicare Advantage 2,053 2,116 4,131 4,208 Medicare Part D 345 410 746 860 Other 1,038 1,227 1,978 2,365 International Health 712 633 1,414 1,274 Total Cigna Healthcare 9,615 9,466 19,141 18,814 International businesses held for sale 737 809 1,500 1,618 Other 74 50 143 108 Intercompany eliminations — (2) (2) (3) Total premiums 10,426 10,323 20,782 20,537 Services (Fees) (ASC 606) Evernorth 1,790 1,456 3,414 2,770 Cigna Healthcare 1,478 1,425 2,974 2,859 Other Operations 4 5 9 10 Other revenues 132 108 147 127 Intercompany eliminations (647) (543) (1,249) (974) Total fees and other revenues 2,757 2,451 5,295 4,792 Total revenues from external customers $ 45,155 $ 42,821 $ 88,746 $ 83,401

Description of Business (Detail

Description of Business (Details) $ in Billions	Jul. 01, 2022 USD ($)
International life, accident and supplemental benefits businesses | Disposed of by Sale | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5.4

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Noninsurance customer receivables	$ 7,578	$ 6,274
Pharmaceutical manufacturers receivables	7,006	5,463
Insurance customer receivables	2,790	2,932
Other receivables	952	456
Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale	18,326	15,125
Accounts receivable, net classified as Assets of businesses held for sale	(36)	(54)
Accounts receivable, net per Consolidated Balance Sheets	$ 18,290	$ 15,071

Accounts Receivable, Net - Narr

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Receivables [Abstract]
Allowance for receivables net current	$ 1,900	$ 1,400
Allowance for current expected credit losses on accounts receivable	$ 75	$ 60

Mergers, Acquisitions and Div_2

Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Apr. 19, 2021
Business Acquisition [Line Items]
Goodwill	$ 45,810		$ 45,810		$ 45,811
Acquired intangible assets	33,276		33,276		$ 34,102
Integration and transaction-related costs (Selling, general and administrative expenses)	36	$ 16	88	$ 45
Integration and transaction-related costs, after-tax	$ 26	$ 14	$ 63	$ 36
MDLIVE, Inc.
Business Acquisition [Line Items]
Ownership interest acquired						97%
Ownership interest after acquisition						100%

Assets and Liabilities of Bus_3

Assets and Liabilities of Businesses Held for Sale (Details) - USD ($) $ in Millions	Jul. 01, 2022	Jun. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Separate account assets		$ 648	$ 878
Assets of businesses held for sale		9,052	10,057
Insurance and contractholder liabilities		4,427	4,644
Total liabilities of businesses held for sale		5,851	6,423
International life, accident and supplemental benefits businesses | Disposed of by Sale | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5,400
International life, accident and supplemental benefits businesses | Held-for-Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		455	406
Investments		4,518	5,109
Deferred policy acquisition costs		2,598	2,755
Separate account assets		648	878
Goodwill, other intangible assets and all other assets		833	909
Assets of businesses held for sale		9,052	10,057
Insurance and contractholder liabilities		4,427	4,644
Accounts payable, accrued expenses and other liabilities		420	452
Deferred tax liabilities, net		356	449
Separate account liabilities		648	878
Total liabilities of businesses held for sale		5,851	6,423
Gross unrealized appreciation on securities and derivatives		(208)	137
Gross translation loss on foreign currencies		$ 366	$ 209

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Shareholders' net income	$ 1,559	$ 1,467	$ 2,742	$ 2,628
Shares:
Weighted average (in shares)	315,122	341,479	316,795	344,845
Common stock equivalents (in shares)	3,182	3,450	2,989	3,589
Total shares (in shares)	318,304	344,929	319,784	348,434
EPS, basic (in dollars per share)	$ 4.95	$ 4.30	$ 8.66	$ 7.62
EPS, effect of dilution (in dollars per share)	(0.05)	(0.05)	(0.09)	(0.08)
EPS, diluted (in dollars per share)	$ 4.90	$ 4.25	$ 8.57	$ 7.54

Earnings Per Share - Outstandin

Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options (in shares)	1.3	1.5	2	1.5

Earnings Per Share - Shares of

Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares shares in Millions	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Earnings Per Share [Abstract]
Shares of common stock held in treasury	81.3	71.2	52.2

Debt - Outstanding Amounts of D

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Short-term debt
Commercial paper	$ 1,797,000,000	$ 2,027,000,000
Other, including finance leases	23,000,000	23,000,000
Total short-term debt	2,397,000,000	2,545,000,000
Long-term debt
Other, including finance leases	35,000,000	28,000,000
Total long-term debt	30,984,000,000	31,125,000,000
$500 million, 3.05% Notes due 11/2022
Short-term debt
Current maturities	497,000,000	495,000,000
Long-term debt
Gross value	$ 500,000,000
Interest Rate	3.05%
$17 million, 8.3% Notes due 2023
Short-term debt
Current maturities	$ 17,000,000	0
Long-term debt
Long-term debt	0	17,000,000
Gross value	$ 17,000,000
Interest Rate	8.30%
$63 million, 7.65% Notes due 2023
Short-term debt
Current maturities	$ 63,000,000	0
Long-term debt
Long-term debt	0	63,000,000
Gross value	$ 63,000,000
Interest Rate	7.65%
$700 million, Floating Rate Notes due 2023
Long-term debt
Long-term debt	$ 699,000,000	699,000,000
Gross value	700,000,000
$1,000 million, 3% Notes due 2023
Long-term debt
Long-term debt	989,000,000	985,000,000
Gross value	$ 1,000,000,000
Interest Rate	3%
$1,187 million, 3.75% Notes due 2023
Long-term debt
Long-term debt	$ 1,186,000,000	1,185,000,000
Gross value	$ 1,187,000,000
Interest Rate	3.75%
$500 million, 0.613% Notes due 2024
Long-term debt
Long-term debt	$ 499,000,000	498,000,000
Gross value	$ 500,000,000
Interest Rate	0.613%
$1,000 million, 3.5% Notes due 2024
Long-term debt
Long-term debt	$ 987,000,000	983,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.50%
$900 million, 3.25% Notes due 2025 (1)
Long-term debt
Long-term debt	$ 895,000,000	897,000,000
Gross value	$ 900,000,000
Interest Rate	3.25%
$2,200 million, 4.125% Notes due 2025
Long-term debt
Long-term debt	$ 2,194,000,000	2,193,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.125%
$1,500 million, 4.5% Notes due 2026
Long-term debt
Long-term debt	$ 1,503,000,000	1,504,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.50%
$800 million, 1.25% Notes due 2026
Long-term debt
Long-term debt	$ 797,000,000	796,000,000
Gross value	$ 800,000,000
Interest Rate	1.25%
$1,500 million, 3.4% Notes due 2027
Long-term debt
Long-term debt	$ 1,429,000,000	1,423,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%
$259 million, 7.875% Debentures due 2027
Long-term debt
Long-term debt	$ 259,000,000	259,000,000
Gross value	$ 259,000,000
Interest Rate	7.875%
$600 million, 3.05% Notes due 2027
Long-term debt
Long-term debt	$ 596,000,000	596,000,000
Gross value	$ 600,000,000
Interest Rate	3.05%
$3,800 million, 4.375% Notes due 2028
Long-term debt
Long-term debt	$ 3,783,000,000	3,782,000,000
Gross value	$ 3,800,000,000
Interest Rate	4.375%
$1,500 million, 2.4% Notes due 2030
Long-term debt
Long-term debt	$ 1,491,000,000	1,490,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.40%
$1,500 million, 2.375% Notes due 2031
Long-term debt
Long-term debt	$ 1,414,000,000	1,500,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.375%
$45 million, 8.3% Step Down Notes due 2033
Long-term debt
Long-term debt	$ 45,000,000	45,000,000
Gross value	$ 45,000,000
Interest Rate	8.30%
$190 million, 6.15% Notes due 2036
Long-term debt
Long-term debt	$ 190,000,000	190,000,000
Gross value	$ 190,000,000
Interest Rate	6.15%
$2,200 million, 4.8% Notes due 2038
Long-term debt
Long-term debt	$ 2,192,000,000	2,192,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.80%
$750 million, 3.2% Notes due 2040
Long-term debt
Long-term debt	$ 743,000,000	743,000,000
Gross value	$ 750,000,000
Interest Rate	3.20%
$121 million, 5.875% Notes due 2041
Long-term debt
Long-term debt	$ 119,000,000	119,000,000
Gross value	$ 121,000,000
Interest Rate	5.875%
$448 million, 6.125% Notes due 2041
Long-term debt
Long-term debt	$ 489,000,000	490,000,000
Gross value	$ 448,000,000
Interest Rate	6.125%
$317 million, 5.375% Notes due 2042
Long-term debt
Long-term debt	$ 315,000,000	315,000,000
Gross value	$ 317,000,000
Interest Rate	5.375%
$1,500 million, 4.8% Notes due 2046
Long-term debt
Long-term debt	$ 1,466,000,000	1,465,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.80%
$1,000 million, 3.875% Notes due 2047
Long-term debt
Long-term debt	$ 989,000,000	988,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.875%
$3,000 million, 4.9% Notes due 2048
Long-term debt
Long-term debt	$ 2,968,000,000	2,967,000,000
Gross value	$ 3,000,000,000
Interest Rate	4.90%
$1,250 million, 3.4% Notes due 2050
Long-term debt
Long-term debt	$ 1,236,000,000	1,236,000,000
Gross value	$ 1,250,000,000
Interest Rate	3.40%
$1,500 million, 3.4% Notes due 2051
Long-term debt
Long-term debt	$ 1,476,000,000	$ 1,477,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%

Debt - Narrative (Details)

Debt - Narrative (Details)	1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2022 USD ($) bank	Apr. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Commercial paper average interest rate					1.60%
Interest expense on long-term and short-term debt			$ 316,000,000	$ 311,000,000	$ 630,000,000	$ 636,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity			5,000,000,000		5,000,000,000
Five-year Revolving Credit Agreement, Maturing April 2026
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 3,000,000,000
Credit agreement term		5 years
Three-year Revolving Credit Agreement, Maturing April 2024
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		3 years
364-day Revolving Credit Agreement, Maturing April 2022
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		364 days
Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Outstanding balances			$ 0		$ 0
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 6,500,000,000
Number of participating banks | bank	22
Leverage ratio covenant	60%
Revolving Credit And Letter Of Credit Facility Maturing April 2027
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 3,000,000,000
Credit agreement term	5 years
Credit agreement extension term	1 year
Revolving Credit And Letter Of Credit Facility Maturing April 2027 | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Revolving Credit Facility Maturing April 2025
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	3 years
Credit agreement extension term	1 year
364 Day Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year

Common and Preferred Stock - Na

Common and Preferred Stock - Narrative (Details) - $ / shares		3 Months Ended						6 Months Ended
	Jul. 27, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)		$ 1.12	$ 1.12	$ 1	$ 1	$ 1	$ 1	$ 2.24	$ 2
Subsequent Event
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)	$ 1.12

Common and Preferred Stock - Di

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions					6 Months Ended
	Jun. 23, 2022	Mar. 24, 2022	Jun. 23, 2021	Mar. 25, 2021	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Amount per share (in dollars per share)	$ 1.12	$ 1.12	$ 1	$ 1
Total amount paid	$ 352	$ 357	$ 342	$ 345	$ 709	$ 687

Common and Preferred Stock - Ac

Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details) - USD ($) shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 15, 2022
Accelerated Share Repurchases [Line Items]
Accelerated stock repurchase, amount authorized						$ 3,500,000,000
Stock repurchased		$ 1,006,000,000	$ 865,000,000	$ 2,340,000,000	$ 3,673,000,000
Subsequent Event
Accelerated Share Repurchases [Line Items]
Accelerated stock repurchase, amount remitted	$ 3,500,000,000
Stock repurchased (in shares)	10.4
Treasury Stock
Accelerated Share Repurchases [Line Items]
Stock repurchased		1,006,000,000	865,000,000	2,340,000,000	3,673,000,000
Additional Paid-in Capital
Accelerated Share Repurchases [Line Items]
Stock repurchased		$ 0	$ 0	$ 0	$ 0

Insurance and Contractholder _3

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Current
Contractholder deposit funds	$ 371	$ 352
Future policy benefits	246	312
Unearned premiums	575	558
Total	6,130	5,929
Insurance and contractholder liabilities classified as held for sale	(476)	(611)
Current insurance and contractholder liabilities	5,654	5,318
Non-current
Contractholder deposit funds	6,606	6,702
Future policy benefits	8,454	9,194
Unearned premiums	415	418
Total	15,728	16,596
Insurance and contractholder liabilities classified as held for sale	(3,951)	(4,033)
Non-current insurance and contractholder liabilities	11,777	12,563
Total
Contractholder deposit funds	6,977	7,054	$ 7,122
Future policy benefits	8,700	9,506
Unearned premiums	990	976
Future policy benefits			9,531
Unearned premiums			912
Total	21,858	22,525
Insurance and contractholder liabilities classified as held for sale	(4,427)	(4,644)
Total insurance and contractholder liabilities	17,431	17,881	22,515
Future policy benefits classified as liabilities of business held for sale	3,600	3,800
Unpaid claims classified as liabilities of business held for sale	400	400
Contractholder deposit funds classified as liabilities of business held for sale	400	400
Cigna Healthcare
Current
Unpaid claims and claim expenses	4,432	4,159
Non-current
Unpaid claims and claim expenses	58	102
Total
Unpaid claims and claim expenses	4,490	4,261
Unpaid claims and claim expenses	4,490	4,261	4,228	$ 3,695
Other Operations
Current
Unpaid claims and claim expenses	506	548
Non-current
Unpaid claims and claim expenses	195	180
Total
Unpaid claims and claim expenses	$ 701	$ 728
Unpaid claims and claim expenses			$ 722

Insurance and Contractholder _4

Insurance and Contractholder Liabilities - Narrative (Details) - USD ($) $ in Billions	Jun. 30, 2022	Jun. 30, 2021
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process	$ 4.1	$ 3.9

Insurance and Contractholder _5

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - Cigna Healthcare - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	$ 4,261	$ 3,695
Less: Reinsurance and other amounts recoverable	261	237
Beginning balance, net	4,000	3,458
Incurred costs related to:
Current year	15,751	15,716
Prior years	(268)	(228)
Total incurred	15,483	15,488
Paid costs related to:
Current year	11,900	12,065
Prior years	3,290	2,858
Total paid	15,190	14,923
Ending balance, net	4,293	4,023
Add: Reinsurance and other amounts recoverable	197	205
Ending balance	$ 4,490	$ 4,228

Insurance and Contractholder _6

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 268	$ 228
Favorable (unfavorable) variance, percentage	0.80%	0.80%
Actual completion factors
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 84	$ 92
Favorable (unfavorable) variance, percentage	0.20%	0.30%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 184	$ 136
Favorable (unfavorable) variance, percentage	0.60%	0.50%

Insurance and Contractholder _7

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Liability Balance Details (Details) - Other Operations - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 701	$ 728
Unpaid claims and claim expenses			$ 722
International businesses held for sale and our interest in a joint venture in Türkiye
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	412	$ 447
Unpaid claims and claim expenses			438	$ 452
Other Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 289
Unpaid claims and claim expenses			$ 284

Insurance and Contractholder _8

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Other Operations - Activity (Details) - Other Operations - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance, including disposal groups	$ 728
Paid costs related to:
Ending balance		$ 722
Ending balance, including disposal groups	701
International businesses held for sale and our interest in a joint venture in Türkiye
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance		452
Less: Reinsurance and other amounts recoverable		45
Beginning balance, net		407
Beginning balance, including disposal groups	447
Less: Reinsurance, including disposal groups	46
Beginning balance, net, including disposal groups	401
Incurred claims related to:
Current year	490	501
Prior years	4	(4)
Total incurred	494	497
Paid costs related to:
Current year	306	314
Prior years	187	181
Total paid	493	495
Foreign currency	(28)	(16)
Ending balance, net		393
Add: Reinsurance and other amounts recoverable		45
Ending balance		$ 438
Ending balance, net, including disposal groups	374
Add: Reinsurance, including disposal groups	38
Ending balance, including disposal groups	$ 412

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) reinsurer	Dec. 31, 2021 USD ($) reinsurer
Effects of Reinsurance [Line Items]
Reinsurance recoverables, held for sale	$ 90
GMIB
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100%	100%
Annuitization election period	30 days
Number of external reinsurers | reinsurer	3	3
GMIB | Other Contract [Member]
Effects of Reinsurance [Line Items]
GMIB liabilities	$ 463	$ 572
Variable Annuity | Berkshire Hathaway Life Insurance Company of Nebraska
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100%
Remaining overall limit under reinsurance agreement	$ 3,100
Other Current Assets
Effects of Reinsurance [Line Items]
Reinsurance recoverables	$ 164

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables by Range of External Credit Rating and Collateral Level (Details) $ in Millions	Jun. 30, 2022 USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 5,158
Allowance for uncollectible reinsurance	(30)
Total reinsurance recoverables	5,128
Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,127
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,735
No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	296
Ongoing Operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables	406
Ongoing Operations | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	173
Ongoing Operations | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	61
Ongoing Operations | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	172
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	125
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	125
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4
Ongoing Operations | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	277
Ongoing Operations | No collateral | A- equivalent and higher current ratings (
Ceded Credit Risk [Line Items]
Reinsurance recoverables	173
Ongoing Operations | No collateral | BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	61
Ongoing Operations | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	43
Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4,752
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,870
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	688
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	140
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	394
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	401
Acquisition, disposition or run-off activities | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	243
Acquisition, disposition or run-off activities | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,002
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	260
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	140
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	394
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	208
Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,731
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,870
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	428
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	401
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	19
Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	13
Acquisition, disposition or run-off activities | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	19
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Berkshire Hathaway Life Insurance Company of Nebraska
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Prudential Retirement Insurance and Annuity (marketed under Empower brand)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities | No collateral | A- equivalent and higher current ratings ( | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or run-off activities | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 3

Reinsurance - Account Value, Ne

Reinsurance - Account Value, Net Amount at Risk and Contractholders for GMDB Business (Details) - Variable Annuity - GMDB contractholder in Thousands, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) contractholder	Dec. 31, 2021 USD ($) contractholder
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 7,626	$ 9,795
Net amount at risk	$ 2,264	$ 1,392
Number of contractholders (estimated) | contractholder	160	170

Reinsurance - GMIB Reinsurers (

Reinsurance - GMIB Reinsurers (Details) - GMIB - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Berkshire | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100%
Liberty Re (Bermuda) Ltd. | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100%
Other Contract [Member]
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 489	$ 601
Other Contract [Member] | Berkshire
Ceded Credit Risk [Line Items]
GMIB recoverables	230	283
Other Contract [Member] | Sun Life Assurance Company of Canada
Ceded Credit Risk [Line Items]
GMIB recoverables	136	167
Other Contract [Member] | Liberty Re (Bermuda) Ltd.
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 123	$ 151

Investments - Investments by Ca

Investments - Investments by Category (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current
Investments including assets of business held for sale	$ 1,065	$ 1,264
Investments classified as assets of business held for sale	(311)	(344)
Investments per Consolidated Balance Sheets	754	920
Long-term
Investments including assets of business held for sale	20,931	23,203
Investments classified as assets of business held for sale	(4,207)	(4,765)
Investments per Consolidated Balance Sheets	16,724	18,438
Total
Investments including assets of business held for sale	21,996	24,467
Investments classified as assets of business held for sale	(4,518)	(5,109)
Investments per Consolidated Balance Sheets	17,478	19,358
Debt securities
Current
Investments including assets of business held for sale	784	796
Long-term
Investments including assets of business held for sale	13,166	16,162
Total
Investments including assets of business held for sale	13,950	16,958
Equity securities
Current
Investments including assets of business held for sale	69	0
Long-term
Investments including assets of business held for sale	767	603
Total
Investments including assets of business held for sale	836	603
Commercial mortgage loans
Current
Investments including assets of business held for sale	13	40
Long-term
Investments including assets of business held for sale	1,566	1,526
Total
Investments including assets of business held for sale	1,579	1,566
Policy loans
Current
Investments including assets of business held for sale	0	0
Long-term
Investments including assets of business held for sale	1,325	1,338
Total
Investments including assets of business held for sale	1,325	1,338
Other long-term investments
Current
Investments including assets of business held for sale	0	0
Long-term
Investments including assets of business held for sale	4,107	3,574
Total
Investments including assets of business held for sale	4,107	3,574
Short-term investments
Current
Investments including assets of business held for sale	199	428
Long-term
Investments including assets of business held for sale	0	0
Total
Investments including assets of business held for sale	$ 199	$ 428

Investments - Debt Securities b

Investments - Debt Securities by Contractual Maturity Periods (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Amortized Cost
Due in one year or less	$ 820
Due after one year through five years	4,655
Due after five years through ten years	4,844
Due after ten years	4,206
Mortgage and other asset-backed securities	399
Total	14,924	$ 15,775
Fair Value
Due in one year or less	813
Due after one year through five years	4,454
Due after five years through ten years	4,407
Due after ten years	3,909
Mortgage and other asset-backed securities	367
Total	$ 13,950

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Schedule of Investments [Line Items]
Allowance for credit losses on debt securities
Gain (loss) recognized in the income statement
Gain (loss) recognized in other comprehensive income
Gains (losses) reclassified from other comprehensive income into shareholders' net income
Amounts excluded from assessment of hedge effectiveness
Fair value of assets posted as collateral supporting the fair values of these derivative financial instruments
Fair value of assets held as collateral supporting the fair values of these derivative financial instruments
Equity Securities FV NI | Product Concentration Risk | Health Care Sector
Schedule of Investments [Line Items]
Concentration percentage	65%

Investments - Gross Unrealized

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 14,924	$ 15,775
Allowance for Credit Loss	(45)	(23)
Unrealized Appreciation	272	1,337
Unrealized Depreciation	(1,201)	(131)
Fair Value	13,950	16,958
Run-Off Settlement Annuity Business
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,266	2,262
Allowance for Credit Loss	(5)	(5)
Unrealized Appreciation	220	720
Unrealized Depreciation	(185)	(10)
Fair Value	2,296	2,967
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	303	287
Allowance for Credit Loss	0	0
Unrealized Appreciation	56	101
Unrealized Depreciation	(6)	(1)
Fair Value	353	387
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	157	154
Allowance for Credit Loss	0	0
Unrealized Appreciation	0	17
Unrealized Depreciation	(12)	0
Fair Value	145	171
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,471	2,468
Allowance for Credit Loss	0	0
Unrealized Appreciation	63	194
Unrealized Depreciation	(203)	(46)
Fair Value	2,331	2,616
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	11,594	12,361
Allowance for Credit Loss	(45)	(23)
Unrealized Appreciation	151	1,008
Unrealized Depreciation	(946)	(80)
Fair Value	10,754	13,266
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	399	505
Allowance for Credit Loss	0	0
Unrealized Appreciation	2	17
Unrealized Depreciation	(34)	(4)
Fair Value	$ 367	$ 518

Investments - Summary of Debt S

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Jun. 30, 2022 USD ($) position	Dec. 31, 2021 USD ($) position
More than one year
Total Fair Value	$ 10,443	$ 3,890
Total Amortized Cost	11,644	4,021
Total Unrealized Depreciation	$ (1,201)	$ (131)
Total Number of Issues | position	4,589	1,886
Investment grade | Debt securities
One year or less
Fair Value	$ 8,378	$ 2,785
Amortized Cost	9,258	2,861
Unrealized Depreciation	$ (880)	$ (76)
Number of Issues | position	2,695	909
More than one year
Fair Value	$ 750	$ 382
Amortized Cost	916	412
Unrealized Depreciation	$ (166)	$ (30)
Number of Issues | position	355	143
Below investment grade | Debt securities
One year or less
Fair Value	$ 1,124	$ 561
Amortized Cost	1,252	578
Unrealized Depreciation	$ (128)	$ (17)
Number of Issues | position	1,405	781
More than one year
Fair Value	$ 191	$ 162
Amortized Cost	218	170
Unrealized Depreciation	$ (27)	$ (8)
Number of Issues | position	134	53

Investments - Equity Security I

Investments - Equity Security Investments (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Cost
Equity securities with readily determinable fair values	$ 831	$ 257
Equity securities with no readily determinable fair value	283	270
Total	1,114	527
Carrying Value
Equity securities with readily determinable fair values	426	207
Equity securities with no readily determinable fair value	410	396
Total	$ 836	$ 603

Investments - Summary of the Cr

Investments - Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Schedule of Investments [Line Items]
Allowance for credit losses	$ (9)	$ (6)
Total	$ 1,579	$ 1,566
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.84	1.96
Average Loan-to-Value Ratio	59%	61%
Below 60%
Schedule of Investments [Line Items]
Carrying Value	$ 850	$ 560
Below 60% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.21	2.18
60% to 79%
Schedule of Investments [Line Items]
Carrying Value	$ 567	$ 883
60% to 79% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.49	1.89
80% to 100%
Schedule of Investments [Line Items]
Carrying Value	$ 108	$ 129
80% to 100% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.21	1.47
Greater than 100%
Schedule of Investments [Line Items]
Carrying Value	$ 63	$ 0
Greater than 100% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.04	0

Investments - Carrying Values o

Investments - Carrying Values of Other Long-Term Investments (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Schedule of Investments [Line Items]
Other long term investments	$ 4,107	$ 3,574
Real estate investments
Schedule of Investments [Line Items]
Other long term investments	1,356	1,152
Securities partnerships
Schedule of Investments [Line Items]
Other long term investments	2,499	2,272
Other
Schedule of Investments [Line Items]
Other long term investments	$ 252	$ 150

Investments - Summary of Deriva

Investments - Summary of Derivative Instruments Held (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Designated as Hedging Instrument | Fair Value Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	$ 1,073	$ 1,081
Designated as Hedging Instrument | Fair Value Hedging | Interest rate swap contracts
Derivative [Line Items]
Notional Value	1,500	750
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	526	526
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency forward contracts (1)
Derivative [Line Items]
Notional Value	720	1,380
Not Designated as Hedging Instrument, Economic Hedge | Foreign currency forward contracts (1)
Derivative [Line Items]
Notional Value	$ 730	$ 720

Investments - Realized Gains an

Investments - Realized Gains and Losses on Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Investments [Abstract]
Net realized investment gains (losses), excluding credit loss expense and asset write-downs	$ (71)	$ 60	$ (390)	$ 70
Credit loss (expense) recoveries	(24)	(1)	(24)	(10)
Net realized investment gains (losses), before income taxes	$ (95)	$ 59	$ (414)	$ 60

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Financial assets at fair value:
Debt Securities	$ 13,950	$ 16,958
Equity securities	426	207
Recurring
Financial assets at fair value:
Debt Securities	13,950	16,958
Equity securities	426	207
Short-term investments	199	428
Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	258	143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	54	33
Recurring | Swaps | Short-term investments
Financial assets at fair value:
Derivative assets
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	148	147
Equity securities	9	16
Short-term investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	13,290	16,046
Equity securities	417	160
Short-term investments	199	428
Significant Other Observable Inputs (Level 2) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	258	143
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	54	33
Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	512	765
Equity securities	0	31
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) | Recurring | Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Federal government and agency
Financial assets at fair value:
Debt Securities	353	387
Federal government and agency | Recurring
Financial assets at fair value:
Debt Securities	353	387
Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	148	147
Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	205	240
Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government
Financial assets at fair value:
Debt Securities	145	171
State and local government | Recurring
Financial assets at fair value:
Debt Securities	145	171
State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	145	171
State and local government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government
Financial assets at fair value:
Debt Securities	2,331	2,616
Foreign government | Recurring
Financial assets at fair value:
Debt Securities	2,331	2,616
Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	2,331	2,611
Foreign government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	5
Corporate
Financial assets at fair value:
Debt Securities	10,754	13,266
Corporate | Recurring
Financial assets at fair value:
Debt Securities	10,754	13,266
Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Corporate | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	10,327	12,606
Corporate | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	427	660
Mortgage and other asset-backed
Financial assets at fair value:
Debt Securities	367	518
Mortgage and other asset-backed | Recurring
Financial assets at fair value:
Debt Securities	367	518
Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	282	418
Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	$ 85	$ 100

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - Separate Account Assets - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), , including transfers in and out of Level 3
Separate accounts assets classified in Level 3, including disposal groups, period increase (decrease), including transfers in and out of Level 3
Recurring | Securities partnerships
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected liquidation period after inception			10 years

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 512	$ 765
Corporate and government debt securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 426	$ 664
Corporate and government debt securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Corporate and government debt securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.1200	0.1060
Corporate and government debt securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0320	0.0410
Mortgage and other asset-backed securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 85	$ 100
Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0500	0.0390
Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0180	0.0100
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 1	$ 1

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Transfers into/(out of) Level 3
Change in unrealized gains or losses included in Other comprehensive income (loss), net of tax for assets held at the end of the reporting period	$ (11)	$ 7	$ (25)	$ (9)
Debt and Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance		903		854
Balance	686		796
Total gains (losses) included in shareholders' net income	(2)	(1)	10	(11)
Gains (losses) included in other comprehensive income	(13)	7	(28)	(9)
Gains (losses) required to adjust future policy benefits for settlement annuities	(11)	1	(23)	(7)
Purchases, sales and settlements
Purchases	27	42	76	71
Settlements	(71)	(9)	(152)	(25)
Total purchases, sales and settlements	(44)	33	(76)	46
Transfers into/(out of) Level 3
Transfers into Level 3	17	37	118	123
Transfers out of Level 3	(121)	(126)	(285)	(142)
Total transfers into/(out of) Level 3	(104)	(89)	(167)	(19)
Balance		854		854
Balance	512		512
Total gains (losses) included in Shareholders' net income attributable to instruments held at the reporting date	$ (3)	$ (1)	$ (2)	$ (12)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 436	$ 503
Non-guaranteed separate accounts	6,787	7,870
Subtotal	7,223	8,373
Non-guaranteed separate accounts priced at NAV as a practical expedient	920	842
Total	8,143	9,215
Separate account assets of business classified as held for sale	(648)	(878)
Separate account assets	7,495	8,337
Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	4,200	4,500
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	208	227
Non-guaranteed separate accounts	212	1,130
Subtotal	420	1,357
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	228	276
Non-guaranteed separate accounts	6,326	6,406
Subtotal	6,554	6,682
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0	0
Non-guaranteed separate accounts	249	334
Subtotal	249	334
Significant Unobservable Inputs (Level 3) | Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 200	$ 300

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details) - Separate Account Assets - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 252
Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	920	$ 842
Securities partnerships
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	252
Securities partnerships | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	540	513
Real estate funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Real estate funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Real estate funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Real estate funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 376	325
Hedge funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Hedge funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Hedge funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Hedge funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 4	$ 4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Realized investment losses on assets measured at fair value under certain conditions, after-tax			$ 0	$ 0
Realized investment gains on equity securities with no readily determinable fair value

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Fair Value | Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 30,062	$ 35,621
Fair Value | Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,499	1,598
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,579	1,566
Long-term debt, including current maturities, excluding finance leases	$ 31,526	$ 31,593

Variable Interest Entities (Det

Variable Interest Entities (Details) - entity	Jun. 30, 2022	Dec. 31, 2021
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	0	0

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 46,109	$ 48,155	$ 47,130	$ 50,328
Other comprehensive income (loss), net of tax	(589)	153	(1,199)	(221)
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(1)	(1)	(3)	(5)
Shareholders other comprehensive income (loss), net of tax	(588)	154	(1,196)	(216)
Balance	45,922	48,716	45,922	48,716
Securities and Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	125	627	685	900
Other comprehensive income (loss) before reclassifications, before tax	(541)	170	(1,246)	(172)
Other comprehensive income (loss) before reclassifications, tax	101	(40)	255	25
Other comprehensive income (loss) before reclassifications, after-tax	(440)	130	(991)	(147)
Reclassification adjustment, tax	(8)	3	(6)	2
Net amounts reclassified from AOCI to net income	30	(8)	21	(4)
Shareholders other comprehensive income (loss), net of tax	(410)	122	(970)	(151)
Balance	(285)	749	(285)	749
Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	38	(11)	27	(6)
Translation of foreign currencies
Accumulated Other Comprehensive Income (Loss) [Line Items]
Translation of foreign currencies, before tax	(180)	16	(240)	(98)
Translation of foreign currencies, tax	(26)	0	(29)	(5)
Other comprehensive income (loss), net of tax	(206)	16	(269)	(103)
Translation of foreign currencies attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(1)	(1)	(3)	(5)
Translation of foreign currencies attributable to parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(294)	(130)	(233)	(15)
Shareholders other comprehensive income (loss), net of tax	(205)	17	(266)	(98)
Balance	(499)	(113)	(499)	(113)
Postretirement benefits liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,323)	(1,728)	(1,336)	(1,746)
Other comprehensive income (loss) before reclassifications, before tax	18	0	18	0
Other comprehensive income (loss) before reclassifications, tax	(4)	0	(4)	0
Other comprehensive income (loss) before reclassifications, after-tax	14	0	14	0
Reclassification adjustment, tax	(4)	(5)	(7)	(10)
Net amounts reclassified from AOCI to net income	13	15	26	33
Shareholders other comprehensive income (loss), net of tax	27	15	40	33
Balance	(1,296)	(1,713)	(1,296)	(1,713)
Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	17	19	33	39
Reclassification adjustment for settlement (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	$ 0	$ 1	$ 0	$ 4

Organizational Efficiency Pla_2

Organizational Efficiency Plan - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring and Related Activities [Abstract]
Charge for organizational efficiency plan (Selling, general and administrative expenses)	$ 22	$ 168	$ 0	$ 22	$ 0
Charge for organizational efficiency plan (Selling, general and administrative expenses)	17	119	$ 0	$ 17	$ 0
Restructuring charges, abandonment of leased assets and impairment of property and equipment		59
Restructuring charges, severance costs	22	$ 109
Restructuring charge, severance costs, after-tax	$ 17

Organizational Efficiency Pla_3

Organizational Efficiency Plan - Rollforward of Accrued Liability (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
2022 payments	$ (37)
Second quarter 2022 charge	22	$ 109
Balance, June 30, 2022	$ 88	$ 103

Leases - Operating and Finance

Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Operating leases:
Operating lease ROU assets	$ 445	$ 478
Accrued expenses and other liabilities	151	159
Other non-current liabilities	391	436
Total operating lease liabilities	542	595
Finance leases:
Property and equipment, gross	118	101
Accumulated depreciation	(63)	(51)
Property and equipment, net	55	50
Short-term debt	23	23
Long-term debt	35	28
Total finance lease liabilities	$ 58	$ 51
Balance sheet location of operating lease ROU assets	Other assets	Other assets
Balance sheet location of current operating lease liabilities	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Balance sheet location of non-current operating lease liabilities	Other non-current liabilities	Other non-current liabilities
Balance sheet location of non-current finance lease assets	Property and equipment	Property and equipment
Balance sheet location of current finance lease liabilities	Short-term debt	Short-term debt
Balance sheet location of non-current finance lease liabilities	Long-term debt	Long-term debt
Operating lease ROU assets, held for sale	$ 28	$ 27
Operating lease liabilities, held for sale	$ 22	$ 28

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Consolidated effective tax rate	20.80%	22.20%	21.60%	22.40%

Contingencies and Other Matte_2

Contingencies and Other Matters (Details)			1 Months Ended	6 Months Ended
	Mar. 31, 2022 USD ($)	Apr. 19, 2016 claim	Mar. 31, 2016 USD ($) claim	Jun. 30, 2022 USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Loss contingency accrual provision
Litigation Matters and Regulatory Matters
Commitments And Contingencies [Line Items]
Reserves for litigation matters, pre-tax
Express Scripts Litigation with Elevance
Commitments And Contingencies [Line Items]
Number of counts dismissed | claim		2
Number of counts | claim			6
Express Scripts Litigation with Elevance | Judicial Ruling | Pricing Concessions
Commitments And Contingencies [Line Items]
Damages sought by Elevance	$ 14,800,000,000
Express Scripts Litigation with Elevance | Judicial Ruling | Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 13,000,000,000
Express Scripts Litigation with Elevance | Judicial Ruling | Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Elevance			1,800,000,000
Express Scripts Litigation with Elevance | Pending Litigation | Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 150,000,000
Indemnification obligations
Commitments And Contingencies [Line Items]
Liability for guarantees				0
Retiree and Life Insurance Benefits | Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure				430,000,000
Assets maintained by employers (minimum)				430,000,000
Liability for guarantees				$ 0

Segment Information - Summary o

Segment Information - Summary of Special Items (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
After-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	$ 26		$ 14	$ 63	$ 36
Charge for organizational efficiency plan (Selling, general and administrative expenses)	17	$ 119	0	17	0
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	(20)		0	(20)	(21)
Debt extinguishment costs	0		9	0	110
Total impact from special items	23		23	60	125
Before-tax
Integration and transaction-related costs (Selling, general and administrative expenses)	36		16	88	45
Charge for organizational efficiency plan (Selling, general and administrative expenses)	22	$ 168	0	22	0
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	(28)		0	(28)	(27)
Debt extinguishment costs	0		10	0	141
Total impact from special items	$ 30		$ 26	$ 82	$ 159

Segment Information - Summarize

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Revenues from customers	$ 45,155		$ 42,821	$ 88,746	$ 83,401
Net investment income	325		310	739	701
TOTAL REVENUES	45,480		43,131	89,485	84,102
Net realized investment results from certain equity method investments	(49)		(24)	54	(10)
Adjusted revenues	45,431		43,107	89,539	84,092
Depreciation and amortization				1,476	1,446
Income before income taxes	1,985		1,898	3,534	3,411
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(15)		(11)	(32)	(23)
Net realized investment (gains) losses	46		(83)	468	(70)
Amortization of acquired intangible assets	501		503	959	998
Special items
Integration and transaction-related costs	36		16	88	45
Charge for organizational efficiency plan	22	$ 168	0	22	0
(Benefits) charges associated with litigation matters	(28)		0	(28)	(27)
Debt extinguishment costs	0		10	0	141
Pre-tax adjusted income (loss) from operations	2,547		2,333	5,011	4,475
Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	33,716		31,553	66,005	60,972
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	10,622		10,403	21,083	20,688
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	817		865	1,658	1,741
Operating Segments | Evernorth
Segment Reporting Information [Line Items]
Net investment income	16		5	26	8
TOTAL REVENUES	34,863		32,592	68,449	63,212
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	34,863		32,592	68,449	63,212
Income before income taxes	1,044		929	1,914	1,678
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(13)		(6)	(24)	(11)
Net realized investment (gains) losses	0		2	0	4
Amortization of acquired intangible assets	444		488	887	965
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan	0			0
(Benefits) charges associated with litigation matters	0			0	0
Debt extinguishment costs			0		0
Pre-tax adjusted income (loss) from operations	1,475		1,413	2,777	2,636
Operating Segments | Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income	178		180	444	439
TOTAL REVENUES	11,386		11,173	22,675	22,226
Net realized investment results from certain equity method investments	(49)		(24)	54	(10)
Adjusted revenues	11,337		11,149	22,729	22,216
Income before income taxes	1,205		1,111	2,064	2,156
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0		0	(1)	(1)
Net realized investment (gains) losses	(22)		(74)	384	(90)
Amortization of acquired intangible assets	57		12	72	26
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan	0			0
(Benefits) charges associated with litigation matters	0			0	0
Debt extinguishment costs			0		0
Pre-tax adjusted income (loss) from operations	1,240		1,049	2,519	2,091
Operating Segments | Other Operations
Segment Reporting Information [Line Items]
Net investment income	131		125	269	254
TOTAL REVENUES	948		990	1,927	1,995
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	948		990	1,927	1,995
Income before income taxes	167		228	382	434
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(2)		(5)	(7)	(11)
Net realized investment (gains) losses	68		(11)	84	16
Amortization of acquired intangible assets	0		3	0	7
Special items
Integration and transaction-related costs	0		0	0	0
Charge for organizational efficiency plan	0			0
(Benefits) charges associated with litigation matters	0			0	0
Debt extinguishment costs			0		0
Pre-tax adjusted income (loss) from operations	233		215	459	446
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net investment income	0		0	0	0
TOTAL REVENUES	(1,717)		(1,624)	(3,566)	(3,331)
Net realized investment results from certain equity method investments	0		0	0	0
Adjusted revenues	(1,717)		(1,624)	(3,566)	(3,331)
Income before income taxes	(431)		(370)	(826)	(857)
Special items
Pre-tax adjusted income (loss) from operations	(401)		(344)	(744)	(698)
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	0		0	0	0
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0		0	0	0
Net realized investment (gains) losses	0		0	0	0
Amortization of acquired intangible assets	0		0	0	0
Special items
Integration and transaction-related costs	36		16	88	45
Charge for organizational efficiency plan	22			22
(Benefits) charges associated with litigation matters	(28)			(28)	(27)
Debt extinguishment costs			10		141
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(1,717)		(1,624)	(3,566)	(3,331)
Intersegment Eliminations | Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	(1,131)		(1,034)	(2,418)	(2,232)
Intersegment Eliminations | Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(586)		(590)	(1,148)	(1,099)
Intersegment Eliminations | Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ 0		$ 0	$ 0	$ 0

Segment Information - Revenue f

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue from External Customer [Line Items]
Premiums	$ 10,426	$ 10,323	$ 20,782	$ 20,537
Total revenues from external customers	45,155	42,821	88,746	83,401
Intersegment Eliminations
Revenue from External Customer [Line Items]
Premiums	0	(2)	(2)	(3)
Total revenues from external customers	(1,717)	(1,624)	(3,566)	(3,331)
Operating Segments | International businesses held for sale
Revenue from External Customer [Line Items]
Premiums	737	809	1,500	1,618
Operating Segments | Other
Revenue from External Customer [Line Items]
Premiums	74	50	143	108
Evernorth
Revenue from External Customer [Line Items]
Total revenues from external customers	33,716	31,553	66,005	60,972
Evernorth | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(1,131)	(1,034)	(2,418)	(2,232)
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	10,622	10,403	21,083	20,688
Cigna Healthcare | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(586)	(590)	(1,148)	(1,099)
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	817	865	1,658	1,741
Other Operations | Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	0	0	0	0
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenues	31,972	30,047	62,669	58,072
Pharmacy revenues | Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(1,070)	(1,079)	(2,315)	(2,354)
Network revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	16,107	16,166	31,638	31,304
Home delivery and specialty revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	15,268	13,341	29,967	26,115
Other revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,667	1,619	3,379	3,007
Cigna Healthcare | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	9,615	9,466	19,141	18,814
Insured | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	3,771	3,578	7,491	7,101
Stop loss | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,344	1,194	2,669	2,388
Other | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	352	308	712	618
Medicare Advantage | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	2,053	2,116	4,131	4,208
Medicare Part D | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	345	410	746	860
Other | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,038	1,227	1,978	2,365
International Health | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Premiums	712	633	1,414	1,274
Total fees and other revenues
Revenue from External Customer [Line Items]
Revenues	2,757	2,451	5,295	4,792
Total fees and other revenues | Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(647)	(543)	(1,249)	(974)
Fees | Evernorth | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,790	1,456	3,414	2,770
Fees | Cigna Healthcare | Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,478	1,425	2,974	2,859
Fees | Other Operations | Operating Segments
Revenue from External Customer [Line Items]
Revenues	4	5	9	10
Other revenues | Operating Segments
Revenue from External Customer [Line Items]
Revenues	$ 132	$ 108	$ 147	$ 127

Segment Information - Narrative

Segment Information - Narrative (Details) - USD ($) $ in Billions	Jun. 30, 2022	Dec. 31, 2021
Pharmacy Benefits Management Services | Guarantees
Loss Contingencies [Line Items]
Guarantee liability	$ 1	$ 1.1